



Universiteit
Leiden
The Netherlands

Exploring the relationships of gamma-hydroxybutyrate and sleep on metabolism, physiology, and behavior in humans

Pardi, D.J.

Citation

Pardi, D. J. (2019, January 24). *Exploring the relationships of gamma-hydroxybutyrate and sleep on metabolism, physiology, and behavior in humans*. Retrieved from <https://hdl.handle.net/1887/68643>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/68643>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/68643> holds various files of this Leiden University dissertation.


Author: Pardi, D.J.

Title: Exploring the relationships of gamma-hydroxybutyrate and sleep on metabolism, physiology, and behavior in humans

Issue Date: 2019-01-24

CHAPTER 11

Summary, Conclusions & Future Perspectives



Summary and conclusions

Part I - Neurobiological and Clinical Effects of Sodium Oxybate

GHB is an endogenous short-chain fatty acid synthesized locally within the CNS, mostly from its parent compound GABA. Approximately 1–2% of GABA converts to GHB, which is relatively rapidly converted into CO₂ and H₂O through the Krebs cycle. GHB for exogenous administration was first synthesized in the early 1960s and found to readily cross the blood-brain barrier into the CNS, where it displays distinct pharmacological effects. Evidence suggests a role for GHB as a neuromodulator/neurotransmitter, as GHB is synthesized in neurons heterogeneously distributed throughout the CNS, stored in vesicles, released via potassium-dependent depolarization into the synaptic cleft, and undergoes reuptake into the nerve terminal. Under endogenous conditions and concentrations, and depending on the cell group affected, GHB may increase or decrease neuronal activity by inhibiting the release of the primary co-localized neurotransmitter. For example, GHB may decrease neuronal activity when inhibiting the release of the excitatory neurotransmitter dopamine and increase neuronal activity when inhibiting the release of the inhibitory neurotransmitter GABA.

Sodium oxybate is the sodium salt of GHB used for its exogenous oral administration. The behavioral effects induced by SXB appear to be mediated by GHB acting as a neuromodulator/neurotransmitter at GABA_B receptors. After exogenous administration, it is likely that GHB acts at GHB binding site(s) and GABA_B receptors, although it appears that most of the behavioral effects are mediated through the GABA_B receptor. On neurons, supraphysiological concentrations of GHB have a qualitatively different effect than endogenous GHB concentrations. These elevated levels, mostly acting through GABA_B modulation on various neuron groups, decrease neuronal activity. On washout from supraphysiological concentrations, increased neuronal responsiveness has been observed. This activity may underlie the sleep modulation seen when GHB is administered before nighttime sleep onset and, conversely, the wakefulness stimulating effects observed during the day following nighttime administration.

A review of the pharmacology and physiological actions of GHB and SXB is presented in the first part of Chapter 2. In the second part of the same chapter, I review the evidence supporting a modulatory effect of GHB and SXB on sleep and wakefulness, both in healthy and in clinical populations. In Chapter 3, I examine the safety and efficacy of SXB in individuals with PD and sleep disorders. In Chapter 4, I analyze the effect of nightly SXB administration on nocturnal sleep disruption in narcolepsy patients, a subject to which I return in Chapter 6. In Chapter 5, I review and compare the accessibility, purity, dosing, and misuse of illicit GHB and pharmaceutical SXB. In Chapter 7, I evaluate a possible association between narcolepsy, hypocretin neurons, the hormones ghrelin and leptin, and SXB.

GHB and SXB modulate sleep and wakefulness in healthy and in clinical populations

GHB has shown a dose-dependent effect in decreasing sleep onset latency, promoting delta activity and enhancing sleep maintenance. These effects have been reported in both healthy and clinical populations. A review of these effects is presented in the second part of Chapter 2.

In healthy subjects, GHB has been shown to decrease sleep onset latency, promote delta activity, and enhance SWS and sleep maintenance^{14,46,184,239}. Similar effects have been described in clinical contexts. Evidence indicates that GHB/SXB may improve sleep in patients with insomnia^{47,246}. Patients with fibromyalgia have also benefited from similar effects, with GHB/SXB being effective in decreasing not only sleep disruption, but also pain, fatigue and overall multidimensional function^{37,38,228,229,250}. The beneficial effects of GHB/SXB in modulating sleep also extend to patients with neurodegenerative diseases. In the context of Alzheimer's disease, an association between NREM sleep impairment and disease pathogenesis has been revealed^{267,268}, with poor sleep correlating with the severity of cortical A β burden in Alzheimer's disease patients^{272,273}. Given the effects of GHB in increasing NREM SWS⁴⁶, this establishes a therapeutic potential for GHB on Alzheimer's disease pathogenic processes.

In narcolepsy, the results of large, multicenter trials corroborate earlier work and demonstrate a consistent effect of SXB on SWS activity, yielding substantial, dose-related increases in SWS duration and delta power. Additionally, dose-related reductions in stage 1 sleep and number of awakenings are apparent in the larger studies, as well as modest increases in total sleep duration and reductions in REM sleep duration at a dose of 9 g. Multiple measures of daytime sleepiness demonstrated consistent short- and long-term improvement when SXB was administered in combination with stimulant therapy or as the only wake-promoting treatment. In addition, compared with modafinil, SXB as monotherapy appears to produce equal or greater improvement in daytime sleepiness in patients with narcolepsy with, or without, co-morbid cataplexy^{174,290,292-295}.

SXB can decrease excessive daytime sleepiness and fatigue in Parkinson's disease

Excessive daytime sleepiness and nocturnal sleep dysfunction associated with Parkinson's disease have been well documented. However, a correlation between them had not been confirmed, and no specific treatments for nocturnal sleep problems in the Parkinson's disease population had been explored. In chapter 3, the possibility of using SXB for EDS in subjects with Parkinson's disease was evaluated in a multicenter, open-label, polysomnographic study¹. It was hypothesized that using SXB as a treatment for nocturnal sleep dysfunction could also have a therapeutic effect in Parkinson's disease-associated EDS.

Twenty-seven subjects with Parkinson's disease completed the study. The subjects started SXB therapy at a dose of 4.5 g per night, taken in 2 equal doses of 2.25 g, at bedtime and 2.5 to 4 hours later. After 2 weeks, the dose was increased to 6 g per night, and then increased weekly by 1.5 g to a maximum nightly dose of 9 g

(mean dose of 7.8 g SXB per night for 6 weeks). ESS scores were used as the primary efficacy point. The Fatigue Severity Scale, the Pittsburgh Sleep Quality Inventory, and PSG were assessed as secondary measures of daytime symptoms (FSS) and nocturnal symptoms (PSQI and PSG).

Overall, nightly administration of SXB increased SWS, decreased subjective nighttime and daytime sleep problems, and reduced daytime fatigue in individuals with Parkinson's disease. Improvements in the subjective ESS were similar to or better than those observed while using SXB as therapy for narcolepsy^{297,299}. SXB was generally well tolerated.

These results indicate that nightly SXB administration can have beneficial effects on EDS and fatigue associated with Parkinson's disease. These findings also highlight the potential relevance of SXB as a therapeutic tool for Parkinson's disease-associated sleep dysfunctions.

SXB can reduce measures of sleep disruption and increase SWS in patients with narcolepsy.

PSG studies have repeatedly demonstrated pathological changes in the nocturnal sleep of patients with narcolepsy^{525–527}. Therapeutic approaches for narcolepsy-associated nocturnal sleep disruption have provided limited benefit in improving daytime symptoms. Likewise, therapies for daytime symptoms of narcolepsy have provided little benefit for disrupted nocturnal sleep⁵²⁸.

Multiple studies have reported improvements in subjective and objective measures of nocturnal sleep and daytime symptoms in patients with narcolepsy after nightly administration of SXB^{172,291,294,295}. One such study demonstrated that 8 weeks of nightly SXB administration robustly increased stage 3 and 4 sleep and delta power, while the frequency of nocturnal awakenings significantly decreased²⁹⁸, with these changes being associated with significant improvements in daytime narcolepsy symptoms^{49,298}.

Chapter 4 aims at further characterizing the efficacy of SXB for the treatment of EDS in patients with narcolepsy. A double-blind, placebo-controlled study was conducted in patients with narcolepsy undergoing stable therapy with modafinil (200–600 mg/day) for the treatment of EDS². The effect of SXB was assessed both as monotherapy and in combination with modafinil. The intent-to-treat population consisted of 222 patients randomized to receive treatment with placebo (n=55), SXB (n=50), modafinil (n=63), or SXB + modafinil (n=54).

Patients receiving modafinil maintained their previous dosage. Patients receiving SXB started the trial at a dose of 6 g/night, administered in two equal doses (at bedtime and 2.5–4 h later) for the first 4 weeks; the dose of SXB was then increased to 9 g/night for an additional 4 weeks. Treatment efficacy was assessed using overnight PSG, ESS and Maintenance of Wakefulness Test scores, and daily diary recordings.

After 4 weeks of treatment, patients treated with SXB, either alone or in combination with modafinil, showed significant increases in stage 3 and 4 sleep. SXB/modafinil-treated patients also demonstrated significant increases in total NREM sleep and delta power, along with decreased stage 1 sleep and nocturnal awakenings. After an additional 4 weeks of treatment with SXB at the 9 g/night dose, these changes became even more robust and were statistically significant in both SXB groups. It remained unclear whether this increased robustness of effects was related to the dose (6 or 9 g/night), the duration of SXB treatment (4 or 8 weeks), or both.

MWT sleep latency was significantly increased in SXB/modafinil-treated patients, compared to baseline modafinil treatment, whereas patients receiving either modafinil or SXB alone showed no significant change in MWT sleep latency. SXB-treated patients and SXB/modafinil-treated patients also experienced significant improvements in ESS scores, as had been previously reported in detail²⁹⁹.

The results from this trial, the first controlled study evaluating SXB as a single agent for the treatment of EDS in narcolepsy, suggested that, in addition to improving EDS, the nightly administration of SXB was associated with reduced nocturnal sleep disruption and improved sleep continuity, as indicated by the observed decreases in nighttime awakenings and increases in stage 3 and 4 sleep.

SXB has less risk of misuse and abuse than illicit GBH

Gamma-hydroxybutyrate sodium is the chemical name for SXB, but the acronym GHB also refers to the illicit formulations of the drug. Reports of abuse of illicit GHB as a “club drug” and “date-rape drug” have led to the scheduling of GHB as a controlled substance. The use of the chemical name ‘GHB’ to refer to both illicit GHB and to SXB has blurred the distinction between them and has clouded the notion that illicit GHB and SXB have different risks or liabilities of abuse.

In Chapter 5, I address this issue by means of a review that aims at summarizing the differences in accessibility, purity, dosing, and relative abuse liability of pharmaceutical SXB (Xyrem®) and illicit GHB, focusing on the availability and prevalence of non-medical use, and the risks and consequences of misuse and abuse³.

This review draws information from three types of sources: data from the peer-reviewed scientific literature; data from national surveys of drug use, abuse, and law enforcement activity in the U.S., Europe, and Australia; and data from clinical trials and post-marketing surveillance from Jazz Pharmaceuticals on the rates of abuse, diversion, drug-facilitated sexual assault, and deaths associated with SXB.

Data presented in this review supports the conclusion that there are substantial differences in the availability, purity, and dosing of illicit GHB compared to pharmaceutical SXB, and that the risks associated with illicit GHB are greater than those associated with pharmaceutical SXB. This review shows that the prevalence of illicit GHB use, abuse, intoxication and overdose has declined in the U.S. since it

became illegal, and that the abuse and misuse of pharmaceutical SXB has been rare since its introduction to the market.

SXB can improve sleep fragmentation associated with narcolepsy

In Chapter 6, I extend the studies from Chapter 4 by further analyzing the effects of nightly SXB administration on nocturnal sleep in narcolepsy patients. Chapter 6 describes the first large randomized, double-blind, placebo-controlled, parallel group trial examining the impact of SXB on sleep architecture and narcolepsy symptoms⁴. The data presented in this chapter focus on the changes in nocturnal PSG parameters, providing additional information on the effects of SXB on nocturnal sleep.

The trial was conducted with 228 adult patients with narcolepsy/cataplexy in the U.S., Canada, and Europe. Patients received either 4.5, 6, or 9 g/night of SXB or placebo, administered in 2 equally divided doses each night for 8 weeks. Following randomization, patients were started on placebo in single-blind fashion and recorded baseline cataplexy occurrences over a 14-day period. After the baseline analysis, patients started receiving SXB or placebo, and were titrated to their final dose during the first 4 weeks of treatment. Patients were then maintained at their assigned dose for the remaining 4 weeks of the study, before returning for the final efficacy and safety assessments. PSG and MWT were performed, and changes in narcolepsy symptoms and adverse events were recorded in daily diaries.

Results showed that sleep latency was not significantly altered at any dose or treatment time. Total sleep time was significantly increased at the 8th week of treatment with the 9 g/night dose. The number of nocturnal awakenings significantly decreased at 4 weeks with all doses and remained so with the 6 and 9 g/night doses at 8 weeks. Wake after sleep onset significantly decreased in the 9 g/night group at 8 weeks. There was a significant association between dose and increased total sleep time, decreased number of awakenings, and decreased wake after sleep onset at 8 weeks.

The duration of stage 1 sleep was significantly decreased with all SXB doses at 4 weeks and remained so with the 6 and 9 g/night doses at 8 weeks; a significant dose association for the decrease in stage 1 sleep was found. The duration of stage 2 sleep was unaltered. The duration of stage 3 and 4 sleep was significantly increased with the 6 g/night and 9 g/night groups at 4 weeks and with all SXB doses at 8 weeks, being significantly dose-dependent at both 4 weeks and 8 weeks. Median delta power was significantly increased with all SXB doses at both 4 and 8 weeks, but a significant dose relationship was not observed. The duration of REM sleep was significantly decreased with the 9 g/night dose at 4 and 8 weeks.

Other measures of efficacy, reported elsewhere, indicated that the nightly administration of 4.5, 6, and 9 g/night doses of SXB significantly decreased cataplexy attacks, and significantly improved subjective and objective measures of EDS and quality of life^{49,298,529}.

These results indicated that SXB induces dose-related improvements in measures of sleep continuity and that SXB may improve the sleep fragmentation that is commonly associated with narcolepsy. The continued improvements from week 4 to week 8 also suggest a possible time-dependent effect.

SXB's influence on BMI is unlikely to involve changes in the secretion of ghrelin or leptin

Ghrelin and leptin, two hormones with important roles in regulating energy homeostasis^{201,375,376,381}, can be directly sensed by hypocretin neurons, and their interaction with the hypocretin system has been shown to be involved in ingestive behavior²⁰².

Because hypocretin influences sympathetic nervous system activity, which in turn can affect the expression of both leptin and ghrelin, hypocretin deficiency may lead to altered levels of these hormones, potentially affecting ingestive behavior and energy metabolism.

In narcolepsy patients, altered ingestive behavior and obesity are commonly observed and have been associated with hypocretin deficiency⁵³⁰⁻⁵³². Since the hypocretin system has a key role in the regulation of sleep and wakefulness, with hypocretin deficiency also being associated with narcolepsy, it is possible that hypocretin deficiency may dysregulate feeding behavior and energy homeostasis. Therefore, in Chapter 7, I examine the link between narcolepsy, hypocretin neurons, the hormones ghrelin and leptin, and SXB, aiming at evaluating whether human hypocretin deficiency or SXB can alter the levels of these hormones, which could help explain the altered ingestive behavior and increased BMI seen in narcolepsy patients⁵. We investigated whether total blood ghrelin or leptin levels are altered in hypocretin-deficient narcoleptic patients compared to controls, and whether total ghrelin or leptin levels are influenced by SXB.

Eight medication-free, male hypocretin-deficient narcolepsy with cataplexy patients and 8 healthy male controls, matched for age, BMI, and body fat percentage were included in this study. Plasma total ghrelin and leptin levels were assessed at baseline and after 5 consecutive nights of SXB treatment at a total dose of 6 g/night, administered in two equal doses of 3 g, 4 hours apart. PSG recordings were also performed.

Both in controls and in narcolepsy patients, administration of SXB resulted in a significant decrease in stages 1/2 NREM and REM sleep over 24 hours, while at night, awakenings were significantly reduced and the percentage of SWS increased more than 2-fold. During the day, time spent in stages 1/2 NREM and REM sleep was reduced, and a trend towards longer periods of wakefulness was observed. No differences in ghrelin or leptin levels nor any effects of SXB on the plasma levels of either hormone were found.

Even though a small number of patients was included in this study, the small intergroup differences indicate that the increased BMI of narcolepsy patients is

unlikely to be mediated by hypocretin deficiency-mediated changes in total ghrelin or leptin levels, and that SXB's influence on body weight is unlikely to involve changes in the secretion of the hormones.

Part II: Sleep, Eating, and Metabolism

An overview of the epidemiological evidence linking sleep and obesity is presented in Chapter 8. In addition, I discuss how sleep affects metabolic, endocrine, immune, and circadian processes, how brain-processing circuits and functions are affected by sleep loss, and how this altered brain function can influence eating behavior. Chapter 9 discusses how manipulation of a single night of sleep may influence food preferences in humans. Chapter 10 examines how a short, outdoor excursion under Paleolithic-like eating, living, and sleeping conditions improves physiological and metabolic parameters in the body.

Epidemiology shows a correlation between sleep loss and obesity

The first part of Chapter 8 addresses the question of whether there is an epidemiological relationship between sleep loss and obesity. In 2012, 70 million U.S. adults reported getting less than six hours of sleep at night⁵³³. Sleep is a major public health concern, and insufficient sleep is related to motor vehicle crashes, industrial accidents, and medical errors⁵³⁴. Epidemiology studies show that there is a relationship between sleep duration and body weight, and show that sleep disruption impacts metabolism, immune function, and circadian rhythms. Because obesity rates are rising worldwide in adults and children^{305,535}, it will be important to understand how sleep duration and quality affect human health.

Objective measures of sleep reveal that total sleep time has not decreased over the last 50 years

The second part of Chapter 8 addresses the question of whether actual sleep time as decreased in the last 50 years. A literature review found that sleep duration increased in some countries (Bulgaria, Poland, Canada, France, Britain, Korea, and the Netherlands), decreased in others (Japan, Russia, Finland, Germany, Belgium, and Austria), and was inconsistent in the U.S. and Sweden⁵³⁶, and later reports have shown that the number of individuals sleeping 6 hours or less has increased^{537,538}. However, these studies cannot differentiate between people reporting that they sleep less versus people actually sleeping less. Objective measures of sleep duration can only be observed in a sleep laboratory under controlled conditions using sleep-recording techniques like PSG and actigraphy. Researchers first made use of this type of data in a meta-analysis of 65 studies over 40 years to determine that sleep duration decreases with age⁵³⁹. Similarly, other researchers have used this type of data to determine that sleep duration has not decreased over the past 50 years⁵⁴⁰.

Sleep manipulation can drive food preferences in humans

Many laboratory studies and epidemiologic research have shown a connection between reduced sleep and increased weight. However, laboratory studies have used fairly extreme models of sleep in order to observe substantial changes in

metabolic parameters. Chapter 9 discusses how lowered alertness by a moderate change in sleep restriction might drive an individual's food preferences and total calorie consumption.

Fifty healthy, young participants completed two 3-hour study sessions. The first session was a baseline evaluation after an unmodified night of sleep. On the night prior to the second session, the amount of time in bed was manipulated to be 60-130% of an individual's sleep time. Changes in time in bed were linearly associated with changes in scores on the Stanford Sleepiness Scale, so that individuals who had less time in bed were less subjectively alert during the second session. During the middle of each session, participants were allowed to eat from eight different food items with varying degrees of healthfulness, caloric density and distribution, and number of calories.

There was a linear relationship between a change in subjective alertness and a change in total calories consumed and total calories consumed relative to body weight. In addition, there was a positive correlation between subjective alertness and the number of calories consumed from "bad" food choices (i.e., gummy bears, cinnamon-sugar walnuts, toffee peanuts, and sweetened trail mix), but no correlation with the number of calories consumed from "good" food choices (i.e., apple rings, apricots, almonds, and fig bars). There was also a negative association between subjective alertness and the food quality rated by the participants, such that when participants rated themselves less alert, they ate foods that they rated less healthy.

The study showed that manipulation of next-day alertness via the manipulation of sleep for a single night can have a detrimental impact on eating behaviors. Increased subjective feelings of sleepiness correlated with an increase in total calories consumed and with an increase in calories categorized as "bad" by the investigators and "less healthy" by the participants. This study suggests that when a person feels less alert, the hedonic processing for tempting foods may be increased. Previous studies have shown using fMRI that a night of sleep deprivation amplifies regions of the brain responsible for food decisions, and that these changes are associated with a greater desire for caloric density⁵²⁴. In addition, simulation of shift work under experimental conditions increases the likelihood of participants eating high-fat breakfast items compared to that of the control condition⁵⁴¹. This agrees with a study showing that participants consumed a greater percentage of calories from fat compared to carbohydrates the day after a night of total sleep deprivation compared to a day following baseline sleep⁵⁴².

Alternatively, sleep loss might relax personal inhibitions against unhealthy foods. Sleep deprivation alters effort discounting, a principle that suggests that the value attached to a reward is inversely related to the amount of effort required to obtain it⁵⁴³. Perhaps participants with impaired alertness in our study ate unhealthy foods they might have otherwise avoided because they were less likely to make an effort as a result of their sleep deprivation. Sleep loss may also have shifted the focus of participants to foods that subjectively taste better, which correlates with less

healthy foods, from a focus on eating healthier foods. This type of bias has been reported in the context of economic preferences for monetary gambling where sleep deprivation favors the pursuit of large rewards, and reduces minimization of loss⁵⁴⁴. In our study, monetary gains would correspond to the pleasure of eating unhealthy foods, and losses would correspond to the detrimental effects of eating less healthy foods. Thus, sleep-deprived participants may have eaten more of the unhealthy food options because they were more pleasurable and discounted the negative effects of those unhealthy foods.

Importantly, our study examined moderate impairments in sleep loss rather than total sleep deprivation. Insufficient sleep is a major health problem and related to an increase in chronic diseases, such as diabetes, depression, obesity, cancer, increased mortality, and reduced quality of life⁵³⁴. In addition, it has been shown that several consecutive days of chronic sleep restriction below 7 hours results in significant cognitive impairments that accumulate to levels comparable to that after a night of total sleep deprivation⁴⁴⁵. Thus, our study is relevant to food preferences and sleep impairments in modern society and consistent with epidemiological studies that show a relationship between sleep loss and weight gain^{338,545,546}.

A short outdoor excursion under Paleolithic living conditions improves metabolic function and increases weight loss

For more than 2.5 million years, humans have relied on foraging and gathering to supply food. Abundant, regular physical activity under natural lighting and temperature conditions to forage and hunt for food, and large meals in the evening, were the norm. The evolutionarily recent shift to readily available and calorically dense foods has contributed to a wave of 'Western diseases,' such as diabetes and obesity. Permanent food availability, increased meal frequency, and high glycemic foods have resulted in alternating peaks in blood sugar and elevated basal insulin levels^{547,548}, which leads to visceral obesity, glucose intolerance, persistent elevated insulin, and low-grade inflammation⁵⁴⁹⁻⁵⁵¹. As a result, the incidence of type 2 diabetes has been rising worldwide for decades⁵⁵². Furthermore, obesity is caused a chronic imbalance between energy intake and energy expenditure and results in persistent low-grade inflammation throughout the body, such as elevated tumor-necrosis factor alpha (TNF- α), interleukin-1-beta (IL-1 β), and macrophage counts in visceral adipose tissue^{553,554}. TNF- α in cooperation with IL-1 β enhances insulin resistance⁵⁵⁵, and experimentally induced hyperglycemia increases TNF- α and other pro-inflammatory cytokines, such as IL-6 and C-reactive protein⁵⁵⁶⁻⁵⁵⁸. While pancreatic insulin secreted from elevated glucose levels suppresses inflammation⁵⁵⁹⁻⁵⁶¹, this anti-inflammatory effect is reduced in a state of chronic insulin resistance.

Early in our evolutionary history, caloric intake was counterbalanced by its seasonal availability, physical efforts, and knowledge of the surrounding environment^{562,563}. Exercise before eating lowers postprandial inflammation and produces non-inflammatory molecules, such as lactoferrin, immunoglobulin A (IgA), and lysozyme⁵⁶⁴. These molecules are absent or reduced in overweight

individuals⁵⁶⁵ and they have increased postprandial inflammation, which leads to the development of cardiovascular disease, obesity, insulin resistance, and chronic low-grade inflammation^{565–567}. Animal experiments have revealed that caloric restriction and intermittent fasting can suppress weight-gain-related illness and extend lifespan. In mice, caloric restriction increases lifespan by 30–40% by reducing levels of CRP and TNF- α ^{568–570}. Human studies have also begun to reveal the beneficial effects of caloric restriction⁵⁷¹.

In Chapter 10, I describe a study that examines participants on an outdoor nature trip for 4 days under Paleolithic-like living conditions. Individuals lived outdoors without tents and were required to hike throughout the day to simulate the activity level of gathering food. A small snack was provided after noon to mimic the delayed time to gather food, and a meal without modern, processed foods was provided at dinner time. This relatively moderate lifestyle change over a period of 4 days resulted in dramatic improvements in physiological and metabolic parameters. Body weight, body fat, BMI, and visceral fat area all decreased as expected because of reduced caloric intake and increased exercise. Fasting glucose, insulin and HOMA also decreased significantly and CRP, the main indicator of low-grade inflammation, increased. Previously, it has been shown that trips into the forest stimulates human immune function and improves cardiovascular parameters^{572–574}, perhaps as anticipatory protection from bacteria, viruses, insects, or other predators. Natural living in our study may have had similar effects.

This study shows that a short intervention under Paleolithic living conditions can dramatically improve physiological and metabolic parameters, which may aid in the prevention of obesity and type 2 diabetes. The individual factors responsible for these improvements are difficult to parse without further studies that isolate caloric restriction, outdoor activity, and intermittent fasting, but likely a combination of all three were partially responsible for the beneficial effects.

Future perspectives

In Chapter 3, we evaluated the possibility of using SXB for EDS in subjects with Parkinson's disease. Our results provided an indication that nightly SXB administration can have beneficial effects on EDS and fatigue associated with Parkinson's disease. These putative therapeutic effects of SXB are worth pursuing in controlled trials using objective measures of daytime sleepiness. Confirming these results could establish SXB as an important therapeutic tool for Parkinson's disease, with the capacity to improve patients' quality of life.

In Chapter 4, we studied the efficacy of SXB for the treatment of EDS in patients with narcolepsy. The results from this first controlled study evaluating SXB as a single agent for the treatment of EDS in narcolepsy suggested that, in addition to improving EDS, the nightly administration of SXB was associated with reduced nocturnal sleep disruption and improved sleep continuity, as indicated by the decreases in nighttime awakenings and increases in stage 3 and 4 sleep. This study was extended in Chapter 6 by further analyzing the effects of nightly SXB administration on nocturnal sleep in narcolepsy patients. The results indicated that SXB induces dose-related improvements in measures of sleep continuity and that SXB may improve the sleep fragmentation that is commonly associated with narcolepsy.

Although a dose-dependent effect was observed, it remained unclear whether the changes in sleep architecture of narcolepsy patients induced by SXB are related only to the dose or also to the duration of SXB treatment. The continued improvements from week 4 to week 8 suggest a possible time-dependent effect that warrants further clarification.

Additionally, it would be valuable to understand if the observed impact of SXB on sleep EEG activity represents pharmacologically-induced alterations in true sleep-related activity, effects representing anesthetic-like changes, or epiphenomenal EEG activity unrelated to either sleep or anesthesia.

In Chapter 7, we examined the link between narcolepsy, hypocretin neurons, the hormones ghrelin and leptin, and SXB, aiming at evaluating whether human hypocretin deficiency or SXB can alter the levels of these hormones, which could help explain the altered ingestive behavior and increased BMI observed in narcolepsy patients. Given that no differences in ghrelin or leptin levels nor any effects of SXB on the plasma levels of either hormone were found, it is unlikely that changes in total plasma ghrelin or leptin concentrations underlie the increased BMI and altered ingestive behavior in narcolepsy, as well as the effects of SXB administration on BMI.

The small number of patients included in this study calls for further future investigations to confirm these findings and to further evaluate whether or not the sleep-wake instability intrinsic to hypocretin-deficiency drives the altered energy balance associated with narcolepsy.

In Chapter 8, we detailed the epidemiological evidence for the impact of sleep on human health. Future epidemiological studies will need to continue to monitor the rising rates of obesity, and how reduced sleep and impaired sleep quality affect this growing problem. Importantly, sleep is also related to depression, immune function, cancer, circadian rhythms, and other physiological processes. Because sleep is so interconnected to other processes, and loss of sleep has both human health and economic consequences, understanding how to improve and increase sleep will be central to happy workers and healthy economies.

In Chapter 9, we showed that moderate manipulation of alertness via a sleep intervention for a single night can have a detrimental impact on eating behaviors including increased total caloric intake and increased caloric intake from unhealthy foods. However, we did not objectively record sleep with polysomnography or actigraphy, nor was manipulation of sleep controlled in a sleep laboratory. Furthermore, instead of relying on self-reported sleep as the main predictor in our analysis, we used the consequence of sleep loss—subjective daytime sleepiness. Future studies could measure and manipulate sleep loss in a more controlled fashion in a sleep laboratory to determine if objective measures of sleep and impairment correspond to our findings. In addition, because sleep curtailment was relatively mild, this probably reduced the statistical power of our correlation analysis compared to that of studies of severely impaired sleep or total sleep deprivation. Nevertheless, we could detect significant and meaningful correlations between small changes in alertness, typical of sleep disruptions in modern society, and changes in food preferences.

Another caveat of our study is that we could not distinguish between changes in alertness and disruptions in an individual's circadian rhythm. Participants were asked to delay their bedtime, which may have caused a small shift in circadian phase. Future studies could examine melatonin levels in participants to understand the relationship between a participant's circadian rhythms, reduced alertness, and changes in food preferences. In addition, we only analyzed data from 50 participants and 40 of the participants were women. To understand if there are differences between men and women, or to examine other demographic differences, such as ethnicity and age, future studies would need to include a larger sample size.

In Chapter 10, we showed that a 4-day Paleolithic lifestyle change improved many bioelectric and biochemical parameters in study participants, including body weight, body fat, BMI, visceral fat area, fasting glucose, fasting insulin, and HOMA. C-reactive protein, which is a major indicator of low-grade inflammation, increased by an average of approximately 170%. However, we did not distinguish among the effects of caloric restriction, increased exercise, and outdoor living. Future studies could isolate these individual variables to determine which has the most impact on a participant's health. Moreover, an increased number of participants as well as control subjects that do not undergo the intervention would improve the statistical robustness of these preliminary findings.

Another caveat is that the duration of the intervention lasted for only 4 days. It's unclear if the participants' metabolic parameters would return to where they were before the intervention as they re-adapt to modern society. Another possibility is that extended periods of living under Paleolithic-like conditions may cause unintended or unforeseen harm. For example, increased exposure to parasites, bacteria, etc., or other increased environmental stresses could be detrimental to an individual's wellbeing. Future studies could extend the trial intervention to longer periods of time or repeat the intervention at some periodic interval to assess if occasional, short-term natural trips have a longer-term, beneficial impact on health. In any case, this study provides an entry point to examine how simple lifestyle interventions can have dramatic improvements on an individual's health.

References

1. Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. *Arch Neurol* 2008; 65: 1337–1340.
2. Black J, Pardi D, Hornfeldt CS, et al. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. *Sleep Med* 2009; 10: 829–835.
3. Carter LP, Pardi D, Gorsline J, et al. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem®): Differences in characteristics and misuse. *Drug Alcohol Depend* 2009; 104: 1–10.
4. Black J, Pardi D, Hornfeldt CS, et al. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. *J Clin Sleep Med* 2010; 6: 596–602.
5. Donjacour CE, Pardi D, Aziz NA, et al. Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy controls: basal concentrations and response to sodium oxybate. *J Clin Sleep Med* 2013; 9: 797–803.
6. Pardi D, Buman M, Black J, et al. Eating Decisions Based on Alertness Levels After a Single Night of Sleep Manipulation: A Randomized Clinical Trial. *Sleep*; 40. Epub ahead of print February 2017. DOI: 10.1093/sleep/zsw039.
7. Freese J, Pardi DJ, Ruiz-Núñez B, et al. Back to the Future. Metabolic Effects of a 4-Day Outdoor Trip Under Simulated Paleolithic Conditions – New Insights from The Eifel Study. *J Evol Heal*; 1. Epub ahead of print October 2016. DOI: 10.15310/2334-3591.1035.
8. Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. *Nature* 1963; 200: 1207–1208.
9. Roth RH, Giarman NJ. Conversion in vivo of gamma-aminobutyric to gamma-hydroxybutyric acid in the rat. *Biochem Pharmacol* 1969; 18: 247–250.
10. Fishbein WN, Bessman SP. Gamma-Hydroxybutyrate in Mammalian Brain. Reversible Oxidation by Lactic Dehydrogenase. *J Biol Chem* 1964; 239: 357–361.
11. Doherty JD, Hattox SE, Snead OC, et al. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. *J Pharmacol Exp Ther* 1978; 207: 130–139.
12. Snead 3rd OC, Furner R, Liu CC. In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. *Biochem Pharmacol* 1989; 38: 4375–4380.
13. Laborit H. Sodium 4-Hydroxybutyrate. *Int J Neuropharmacol* 1964; 32: 433–451.
14. Helrich M, McAslan TC, Skolnik S, et al. Correlation of Blood Levels of 4-Hydroxybutyrate with State of Consciousness. *Anesthesiology* 1964; 25: 771–775.

15. Blumenfeld M, SRG and HMH. Sodium gamma-hydroxybutyric acid: a new anaesthetic adjuvant. . *Anesth Analg* 1962; 41: 721–726.
16. Laborit G, Larcen A, Kind A. [Electrocardiographic study of sodium 4-hydroxybutyrate.]. *Agressologie* 1963; 4: 77–88.
17. Kleinschmidt S, Grundmann U, Knocke T, et al. Total intravenous anaesthesia with gamma-hydroxybutyrate (GHB) and sufentanil in patients undergoing coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function. *Eur J Anaesthesiol* 1998; 15: 559–564.
18. Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. *Anesth Analg* 1965; 44: 532–539.
19. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. *Electroencephalogr Clin Neurophysiol* 1966; 20: 506–512.
20. Yamada Y, Yamamoto J, Fujiki A, et al. Effect of butyrolactone and gamma-hydroxybutyrate on the EEG and sleep cycle in man. *Electroencephalogr Clin Neurophysiol* 1967; 22: 558–562.
21. Miller JD, Piper IR, Dearden NM. Management of intracranial hypertension in head injury: matching treatment with cause. *Acta Neurochir Suppl* 1993; 57: 152–159.
22. Strong AJ. gamma-Hydroxybutyric acid and intracranial pressure. *Lancet* 1984; 1: 1304.
23. Kolin A, Brezina A, Mamelak M, et al. Cardioprotective action of sodium gamma-hydroxybutyrate against isoproterenol induced myocardial damage. *Int J Exp Pathol* 1993; 74: 275–281.
24. Ueki Y. [Effects of gamma-hydroxybutyrate on monoamine metabolism and protein synthesis after transient global cerebral ischemia]. *No Shinkei Geka* 1992; 20: 937–946.
25. Geldenhuys FG, Sonnendecker EW, De Klrk MC. Experience with sodium-gamma-4-hydroxybutyric acid (gamma-OH) in obstetrics. *J Obs Gynaecol Br Commonw* 1968; 75: 405–413.
26. Ferrara SD, Giorgetti R, Zancaner S, et al. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. *Eur J Clin Pharmacol* 1999; 54: 821–827.
27. Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. *Alcohol Alcohol* 1996; 31: 341–345.
28. Biggio G, Cibin M, Diana M, et al. Suppression of voluntary alcohol intake in rats and alcoholics by gamma-hydroxybutyric acid: a non-GABAergic mechanism. *Adv Biochem Psychopharmacol* 1992; 47: 281–288.
29. Bowles TM, Sommi RW, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. *Pharmacotherapy* 2001; 21: 254–257.

30. Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. *Br J Clin Pharmacol* 1992; 34: 231–235.
31. Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. *Lancet* 1989; 2: 787–789.
32. Gessa GL, Gallimberti L. Gamma-hydroxybutyric acid in the treatment of alcohol dependence. *Clin Neuropharmacol* 1992; 15 Suppl 1: 303A–304A.
33. Maremmani I, Lamanna F, Tagliamonte A. Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics. *J Psychoact Drugs* 2001; 33: 135–142.
34. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, et al. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. *Alcohol Alcohol* 2002; 37: 67–73.
35. Gallimberti L, Cibin M, Pagnin P, et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. *Neuropsychopharmacology* 1993; 9: 77–81.
36. Gallimberti L, Spella MR, Soncini CA, et al. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. *Alcohol* 2000; 20: 257–262.
37. Scharf MB, Baumann M, Berkowitz D V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. *J Rheumatol* 2003; 30: 1070–1074.
38. Scharf MB, Hauck M, Stover R, et al. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. *J Rheumatol* 1998; 25: 1986–1990.
39. Rinaldi F, Puca FM, Mastrosimone F, et al. [On the use of gamma-hydroxybutyrate of sodium in psychiatric therapy]. *Acta Neurol* 1967; 22: 21–41.
40. Martellotta MC, Balducci C, Fattore L, et al. Gamma-hydroxybutyric acid decreases intravenous cocaine self-administration in rats. *Pharmacol Biochem Behav* 1998; 59: 697–702.
41. Vescovi PP, Di Gennaro C. Failure of gammahydroxy butyric acid to stimulate growth hormone secretion in cocaine addicts. *Neuropeptides* 1997; 31: 459–462.
42. Frucht SJ, Bordelon Y, Houghton WH. Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). *Mov Disord* 2005; 20: 745–751.
43. Frucht SJ, Bordelon Y, Houghton WH, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. *Mov Disord* 2005; 20: 1330–1337.
44. Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. *Neurology* 2005; 65: 1967–1969.
45. Rubin BA, Giarmann NJ. The therapy of experimental influenza in mice with antibiotic lactones and related compounds. *Yale J Biol Med* 1947; 19:

- 1017–1023.
46. Lapierre O, Montplaisir J, Lamarre M, et al. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. *Sleep* 1990; 13: 24–30.
 47. Mamelak M, Escriu JM, Stokan O. Sleep-inducing effects of gammahydroxybutyrate. *Lancet* 1973; 2: 328–329.
 48. Fuller DE, Hornfeldt CS, Kelloway JS, et al. The Xyrem risk management program. *Drug Saf* 2004; 27: 293–306.
 49. Xyrem International Study G. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. *Sleep Med* 2005; 6: 415–421.
 50. US Drug Enforcement Administration. Gamma hydroxybutyric acid (GHB, liquid X, Goop, Georgia Home Boy)http://www.usdoj.gov/dea/pubs/pressrel/pr031300_01.htm.
 51. Galloway GP, Frederick SL, Staggers Jr. FE, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. *Addiction* 1997; 92: 89–96.
 52. American Time Use Survey: Sleep Time and Its Relationship to Waking Activities. 2007; 1–11.
 53. Woolverton WL, Rowlett JK, Winger G, et al. Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. *Drug Alcohol Depend* 1999; 54: 137–143.
 54. McMahon LR, Coop A, France CP, et al. Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys. *Eur J Pharmacol* 2003; 466: 113–120.
 55. Carter LP, Richards BD, Mintzer MZ, et al. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. *Neuropsychopharmacology* 2006; 31: 2537–2551.
 56. Anderson I, Kim S, Dyer J, et al. Trends in γ -Hydroxybutyrate (GHB) and Related Drug Intoxication: 1999 to 2003. *Ann Emerg Med* 2006; 47: 177–183.
 57. Drug Abuse Warning Network, 2003: Interim National Estimates of Drug-Related Emergency Department Visits. 2004; 1–104.
 58. Slaughter L. Involvement of drugs in sexual assault. *J Reprod Med* 2000; 45: 425–430.
 59. Doherty JD, Snead OC, Roth RH. A sensitive method for quantitation of gamma-hydroxybutyric acid and gamma-butyrolactone in brain by electron capture gas chromatography. *Anal Biochem* 1975; 69: 268–277.
 60. Ehrhardt JD, Vayer P, Maitre M. A rapid and sensitive method for the determination of gamma-hydroxybutyric acid and trans-gamma-hydroxycrotonic acid in rat brain tissue by gas chromatography/mass spectrometry with negative ion detection. *Biomed Env Mass Spectrom* 1988; 15: 521–524.

61. Snead 3rd OC. gamma-Hydroxybutyric acid in subcellular fractions of rat brain. *J Neurochem* 1987; 48: 196–201.
62. Snead 3rd OC, Morley BJ. Ontogeny of gamma-hydroxybutyric acid. I. Regional concentration in developing rat, monkey and human brain. *Brain Res* 1981; 227: 579–589.
63. Nelson T, Kaufman E, Kline J, et al. The extraneural distribution of gamma-hydroxybutyrate. *J Neurochem* 1981; 37: 1345–1348.
64. Gold BI, Roth RH. Kinetics of in vivo conversion of gamma-[3H]aminobutyric acid to gamma-[3H]hydroxybutyric acid by rat brain. *J Neurochem* 1977; 28: 1069–1073.
65. Weissmann-Nanopoulos Belin, M.F., Mandel, P. and Maitre, M. D. Immunocytochemical evidence for the presence of enzymes synthesizing GABA and GHB in the same neuron. . *Neurochem Intl* 1984; 6: 333–338.
66. Rumigny JF, Cash C, Mandel P, et al. Evidence that a specific succinic semialdehyde reductase is responsible for gamma-hydroxybutyrate synthesis in brain tissue slices. *FEBS Lett* 1981; 134: 96–98.
67. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. *Prog Neurobiol* 1997; 51: 337–361.
68. Eli M, Cattabeni F. Endogenous gamma-hydroxybutyrate in rat brain areas: postmortem changes and effects of drugs interfering with gamma-aminobutyric acid metabolism. *J Neurochem* 1983; 41: 524–530.
69. Rumigny JF, Cash C, Mandel P, et al. Ontogeny and distribution of specific succinic semialdehyde reductase apoenzyme in the rat brain. *Neurochem Res* 1982; 7: 555–561.
70. Rumigny JF, Maitre M, Cash C, et al. Regional and subcellular localization in rat brain of the enzymes that can synthesize gamma-hydroxybutyric acid. *J Neurochem* 1981; 36: 1433–1438.
71. Hearl WG, Churchich JE. A mitochondrial NADP⁺-dependent reductase related to the 4-aminobutyrate shunt. Purification, characterization, and mechanism. *J Biol Chem* 1985; 260: 16361–16366.
72. Cho Song, M.S., Kim, G.Y., Kang, W.D., Choi, E.Y. and Choi, S.Y. SW. Kinetics and mechanism of an NADPH-dependent succinic semialdehyde reductase from bovine brain. . *Eur J Biochem* 1993; 211: 757–762.
73. Barker SA, Snead OC, Poldrugo F, et al. Identification and quantitation of 1,4-butanediol in mammalian tissues: an alternative biosynthetic pathway for gamma-hydroxybutyric acid. *Biochem Pharmacol* 1985; 34: 1849–1852.
74. Roth RH Giarman NJ. LR. Dependence of rat serum lactonase upon calcium. . *Biochem Pharmacol* 1967; 16: 596–598.
75. Doherty JD, Stout RW, Roth RH. Metabolism of (1-14C)gamma-hydroxybutyric acid by rat brain after intraventricular injection. *Biochem Pharmacol* 1975; 24: 469–474.
76. Mohler H, Patel AJ, Balazs. Gamma-hydroxybutyrate degradation in the brain in vivo: negligible direct conversion to GABA. *J Neurochem* 1976; 27: 253–258.

77. Kaufman EE, Nelson T. Evidence for the participation of a cytosolic NADP⁺-dependent oxidoreductase in the catabolism of gamma-hydroxybutyrate in vivo. *J Neurochem* 1987; 48: 1935–1941.
78. Kaufman EE, Nelson T, Goochee C, et al. Purification and characterization of an NADP⁺-linked alcohol oxido-reductase which catalyzes the interconversion of gamma-hydroxybutyrate and succinic semialdehyde. *J Neurochem* 1979; 32: 699–712.
79. Vayer P, Schmitt M, Bourguignon JJ, et al. Evidence for a role of high Km aldehyde reductase in the degradation of endogenous gamma-hydroxybutyrate from rat brain. *FEBS Lett* 1985; 190: 55–60.
80. Kaufman EE, Relkin N, Nelson T. Regulation and properties of an NADP⁺ oxidoreductase which functions as a gamma-hydroxybutyrate dehydrogenase. *J Neurochem* 1983; 40: 1639–1646.
81. Kaufman EE, Nelson T. Kinetics of coupled gamma-hydroxybutyrate oxidation and D-glucuronate reduction by an NADP⁺-dependent oxidoreductase. *J Biol Chem* 1981; 256: 6890–6894.
82. Kaufman EE, Nelson T. An overview of gamma-hydroxybutyrate catabolism: the role of the cytosolic NADP(+)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. *Neurochem Res* 1991; 16: 965–974.
83. Taberner P V, Rick JT, Kerkut GA, et al. The action of gamma-hydroxybutyric acid on cerebral glucose metabolism. *J Neurochem* 1972; 19: 245–254.
84. Snead OC, Bearden LJ, Pegram V, et al. Effect of acute and chronic anticonvulsant administration on endogenous gamma-hydroxybutyrate in rat brain. *Neuropharmacology* 1980; 19: 47–52.
85. Gibson KM. Gamma-hydroxybutyric aciduria: a biochemist's education from a heritable disorder of GABA metabolism. *J Inherit Metab Dis* 2005; 28: 247–65.
86. Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. *Curr Opin Pharmacol* 2006; 6: 44–52.
87. Kaufman EE, Nelson T, Miller D, et al. Oxidation of gamma-hydroxybutyrate to succinic semialdehyde by a mitochondrial pyridine nucleotide-independent enzyme. *J Neurochem* 1988; 51: 1079–1084.
88. Margolis RK. The effect of gamma-hydroxybutyric acid on amino acid levels in brain. *Biochem Pharmacol* 1969; 18: 1243–1246.
89. Mitoma C, Neubauer SE. Gamma-hydroxybutyric acid and sleep. *Experientia* 1968; 24: 12–13.
90. Vayer P, Mandel P, Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. *J Neurochem* 1985; 45: 810–814.
91. Vayer P, Dessort D, Bourguignon JJ, et al. Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain. *Biochem Pharmacol* 1985; 34: 2401–2404.
92. Walkenstein SS, Wiser R, Gudmundsen C, et al. Metabolism of Gamma-Hydroxybutyric Acid. *Biochim Biophys Acta* 1964; 86: 640–642.

93. Maitre M, Cash C, Weissmann-Nanopoulos D, et al. Depolarization-evoked release of gamma-hydroxybutyrate from rat brain slices. *J Neurochem* 1983; 41: 287–290.
94. Maitre M, Mandel P. [Calcium-dependent liberation of gamma-hydroxybutyrate after depolarization of rat brain slices]. *C R Seances Acad Sci III* 1982; 295: 741–743.
95. Vayer P, Maitre M. Regional differences in depolarization-induced release of gamma-hydroxybutyrate from rat brain slices. *Neurosci Lett* 1988; 87: 99–103.
96. Benavides J, Rumigny JF, Bourguignon JJ, et al. High affinity binding sites for gamma-hydroxybutyric acid in rat brain. *Life Sci* 1982; 30: 953–961.
97. Hechler V, Bourguignon JJ, Wermuth CG, et al. gamma-Hydroxybutyrate uptake by rat brain striatal slices. *Neurochem Res* 1985; 10: 387–396.
98. Maitre M, Rumigny JF, Benavides J, et al. High affinity binding site for gamma-hydroxybutyric acid in rat brain. *Adv Biochem Psychopharmacol* 1983; 37: 441–453.
99. Snead 3rd OC, Liu CC. Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. *Biochem Pharmacol* 1984; 33: 2587–2590.
100. Ratomponirina C, Hode Y, Hechler V, et al. gamma-Hydroxybutyrate receptor binding in rat brain is inhibited by guanyl nucleotides and pertussis toxin. *Neurosci Lett* 1995; 189: 51–53.
101. Mamelak M. HD. *Gamma-Hydroxybutyrate and oxidative stress*. . Taylor & Francis, 2002.
102. Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. *Brain Res* 1992; 572: 345–348.
103. Hechler V, Weissmann D, Mach E, et al. Regional distribution of high-affinity gamma-[3H]hydroxybutyrate binding sites as determined by quantitative autoradiography. *J Neurochem* 1987; 49: 1025–1032.
104. Kaupmann K, Cryan JF, Wellendorph P, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. *Eur J Neurosci* 2003; 18: 2722–2730.
105. Kawaguchi Y, Wilson CJ, Augood SJ, et al. Striatal interneurons: chemical, physiological and morphological characterization. *Trends Neurosci* 1995; 18: 527–535.
106. Maitre M, Ratomponirina C, Gobaille S, et al. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. *Eur J Pharmacol* 1994; 256: 211–214.
107. Kemmel V, Taleb O, Perard A, et al. Neurochemical and electrophysiological evidence for the existence of a functional gamma-hydroxybutyrate system in NCB-20 neurons. *Neuroscience* 1998; 86: 989–1000.
108. Cash CD, Gobaille S, Kemmel V, et al. Gamma-hydroxybutyrate receptor

- function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches. *Biochem Pharmacol* 1999; 58: 1815–1819.
109. Kozhechkin SX. Microiontophoretic study of the mechanism of action of gamma-hydroxybutyric acid. *Bull Expl Biol Med* 1979; 88: 1293–1296.
 110. Olpe HR, Koella WP. Inhibition of nigral and neocortical cells by gamma-hydroxybutyrate: a microiontophoretic investigation. *Eur J Pharmacol* 1979; 53: 359–364.
 111. Mathivet P, Bernasconi R, De Barry J, et al. Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABAB receptor agonist. *Eur J Pharmacol* 1997; 321: 67–75.
 112. Bernasconi R, Lauber J, Marescaux C, et al. Experimental absence seizures: potential role of gamma-hydroxybutyric acid and GABAB receptors. *J Neural Transm Suppl* 1992; 35: 155–177.
 113. Madden TE, Johnson SW. Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. *J Pharmacol Exp Ther* 1998; 287: 261–265.
 114. Ocana M, Cendan C, Cobos E, et al. Potassium channels and pain: present realities and future opportunities. *Eur J Pharmacol* 2004; 500: 203–219.
 115. Lingenhoehl K, Brom R, Heid J, et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. *Neuropharmacology* 1999; 38: 1667–1673.
 116. Engberg G, Nissbrandt H. gamma-Hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors. *Naunyn Schmiedebergs Arch Pharmacol* 1993; 348: 491–497.
 117. Williams SR, Turner JP, Crunelli V. Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABAB, receptor-mediated hyperpolarization. *Neuroscience* 1995; 66: 133–141.
 118. Xie X, Smart TG. Gamma-hydroxybutyrate hyperpolarizes hippocampal neurones by activating GABAB receptors. *Eur J Pharmacol* 1992; 212: 291–294.
 119. Godbout R, Pivik RT. EEG and behavioral effects of gamma-hydroxybutyrate in the rabbit. *Life Sci* 1982; 31: 739–748.
 120. Snead 3rd OC. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. *J Neurochem* 2000; 75: 1986–1996.
 121. Vayer P, Gobaille S, Mandel P, et al. 3'-5' cyclic-guanosine monophosphate increase in rat brain hippocampus after gamma-hydroxybutyrate administration. Prevention by valproate and naloxone. *Life Sci* 1987; 41: 605–610.
 122. Ito Y, Ishige K, Zaitso E, et al. gamma-Hydroxybutyric acid increases intracellular Ca²⁺ concentration and nuclear cyclic AMP-responsive element- and activator protein 1 DNA-binding activities through GABAB receptor in cultured cerebellar granule cells. *J Neurochem* 1995; 65: 75–83.
 123. Vayer P, Maitre M. Gamma-hydroxybutyrate stimulation of the formation

- of cyclic GMP and inositol phosphates in rat hippocampal slices. *J Neurochem* 1989; 52: 1382–1387.
124. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. *J Pharmacol Exp Ther* 1979; 208: 7–11.
 125. Shumate JS, Snead 3rd OC. Plasma and central nervous system kinetics of gamma-hydroxybutyrate. *Res Commun Chem Pathol Pharmacol* 1979; 25: 241–256.
 126. Nissbrandt H, Elverfors A, Engberg G. Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. *Synapse* 1994; 17: 217–224.
 127. Roth RH, Doherty JD, Walters JR. Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons? *Brain Res* 1980; 189: 556–560.
 128. Bustos G, Kuhar MJ, Roth RH. Effect of gamma-hydroxybutyrate and gamma-butyrolactone on dopamine synthesis and uptake by rat striatum. *Biochem Pharmacol* 1972; 21: 2649–2652.
 129. Bustos G, Roth RH. Release of monoamines from the striatum and hypothalamus: effect of -hydroxybutyrate. *Br J Pharmacol* 1972; 46: 101–115.
 130. Broxterman HJ, Noach EL, van Valkenburg CF, et al. Cross-tolerance of dopamine metabolism to baclofen, gamma-butyrolactone and HA-966 in the striatum and olfactory tubercle of the rat. *Life Sci* 1981; 28: 973–981.
 131. Da Prada M, Keller HH. Baclofen and gamma-hydroxybutyrate: similar effects on cerebral dopamine neurones. *Life Sci* 1976; 19: 1253–1263.
 132. Kelly PH, Moore KE. Dopamine concentrations in the rat brain following injections into the substantia nigra of baclofen, gamma-aminobutyric acid, gamma-hydroxybutyric acid, apomorphine and amphetamine. *Neuropharmacology* 1978; 17: 169–174.
 133. Waldmeier PC, Fehr B. Effects of baclofen and gamma-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. *Eur J Pharmacol* 1978; 49: 177–184.
 134. Aghajanian GK, Roth RH. Gamma-hydroxybutyrate-induced increase in brain dopamine: localization by fluorescence microscopy. *J Pharmacol Exp Ther* 1970; 175: 131–138.
 135. Dyck LE, Kazakoff CW. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma-butyrolactone. *J Neurosci Res* 1982; 8: 57–65.
 136. Gessa Vargiu, L., Crabai, F., Boero, G.C., Caboni, F., Camba, R. GL. *Selective increase of brain dopamine induced by gamma hydroxybutyrate*. . 1966.
 137. Gessa GL, Crabai F, Yargiu L, et al. Selective increase of brain dopamine induced by gamma-hydroxybutyrate: study of the mechanism of action. *J Neurochem* 1968; 15: 377–381.
 138. Lundborg P, Hedner T, Engel J. Catecholamine concentration in the developing rat brain after gamma-hydroxybutyric acid. *J Neurochem* 1980;

- 35: 425–429.
139. Pericic D, Walters JR. Dopamine in substantia nigra and cortex after gamma-butyrolactone treatment. *J Pharm Pharmacol* 1976; 28: 527–530.
 140. Spano PF, Tagliamonte A, Tagliamonte P, et al. Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate. *J Neurochem* 1971; 18: 1831–1836.
 141. Hedner T, Lundborg P. Effect of gamma-hydroxybutyric acid on catecholamine synthesis and utilization in the developing rat brain. *J Neural Transm* 1982; 54: 19–28.
 142. Roth RH, Nowicky MC, Walters JR, et al. gamma-Hydroxybutyrate: effects on nonstriatal dopaminergic neurons. *Adv Biochem Psychopharmacol* 1977; 16: 483–488.
 143. Roth RH, Suhr Y. Mechanism of the gamma-hydroxybutyrate-induced increase in brain dopamine and its relationship to 'sleep'. *Biochem Pharmacol* 1970; 19: 3001–3012.
 144. Walters JR, Roth RH. Dopaminergic neurons: drug-induced antagonism of the increase in tyrosine hydroxylase activity produced by cessation of impulse flow. *J Pharmacol Exp Ther* 1974; 191: 82–91.
 145. Walters JR, Roth RH. Dopaminergic neurons - alteration in the sensitivity of tyrosine hydroxylase to inhibition by endovenous dopamine after cessation of impulse flow. *Biochem Pharmacol* 1976; 25: 649–654.
 146. Zivkovic B, Guidotti A, Costa E. The regulation of striatal tyrosine hydroxylase. Effects of gamma hydroxybutyric acid and haloperidol. *Naunyn Schmiedebergs Arch Pharmacol* 1975; 291: 193–200.
 147. Arluison M, Javoy-Agid F, Feuerstein C, et al. Histofluorescence analysis of several systems of catecholaminergic nerve fibres within the rat neostriatum revealed by either restricted lesions of the substantia nigra or gamma-hydroxybutyrate. *Brain Res Bull* 1982; 9: 355–365.
 148. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. *Gen Pharmacol* 1992; 23: 1027–1034.
 149. Chéramy A, Nieoullon A, Glowinski J. Stimulating effects of gamma-hydroxybutyrate on dopamine release from the caudate nucleus and the substantia nigra of the cat. *J Pharmacol Exp Ther* 1977; 203: 283–293.
 150. Hechler V, Gobaille S, Bourguignon JJ, et al. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. *J Neurochem* 1991; 56: 938–944.
 151. Biggio G, Casu M, Corda MG, et al. Effect of muscimol, a GABA-mimetic agent, on dopamine metabolism in the mouse brain. *Life Sci* 1977; 21: 525–531.
 152. Snead 3rd OC, Bearden LJ. Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate. *Neurology* 1980; 30: 832–838.
 153. Dingledine R, Iversen LL, Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. *Eur J Pharmacol* 1978; 47: 19–27.

154. Schmidt-Mutter C, Muller C, Zwiller J, et al. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. *Neuropsychopharmacology* 1999; 21: 662–669.
155. Miguez I, Aldegunde M, Duran R, et al. Effect of low doses of gamma-hydroxybutyric acid on serotonin, noradrenaline, and dopamine concentrations in rat brain areas. *Neurochem Res* 1988; 13: 531–533.
156. Spano E. PF and P. Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate. . *Pharmacol Res Commun* 1973; 5: 55–69.
157. Boadle-Biber MC. *Biosynthesis of serotonin*. . New York.: N.N. Osborne. Wiley, 1982.
158. Gerra G, Caccavari R, Fontanesi B, et al. Naloxone and metergoline effects on growth hormone response to gamma-hydroxybutyric acid. *Int Clin Psychopharmacol* 1995; 10: 245–250.
159. Delitala G, Masala A, Alagna S, et al. Growth hormone and prolactin release in acromegalic patients following metergoline administration. *J Clin Endocrinol Metab* 1976; 43: 1382–1386.
160. Lason W, Przewlocka B, Przewlocki R. The effect of gamma-hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain. *Life Sci* 1983; 33 Suppl 1: 599–602.
161. Prodynorphin and proenkephalin mRNAs are increased in rat brain after acute and chronic administration of gamma-hydroxybutyrate. 1999; 1–4.
162. Vayer P, Mandel P, Maitre M. Gamma-hydroxybutyrate, a possible neurotransmitter. *Life Sci* 1987; 41: 1547–1557.
163. Crosby G, Ito M, Kaufman E, et al. Naloxone pretreatment alters the local cerebral metabolic effect of gamma-hydroxybutyrate in rats. *Brain Res* 1983; 275: 194–197.
164. Devoto P, Colombo G, Cappai F, et al. Naloxone antagonizes ethanol- but not gamma-hydroxybutyrate-induced sleep in mice. *Eur J Pharmacol* 1994; 252: 321–324.
165. Gobaille S, Schmidt C, Cupo A, et al. Characterization of methionine-enkephalin release in the rat striatum by in vivo dialysis: effects of gamma-hydroxybutyrate on cellular and extracellular methionine-enkephalin levels. *Neuroscience* 1994; 60: 637–648.
166. Sethy VH, Roth RH, Walters JR, et al. Effect of anesthetic doses of gamma-hydroxybutyrate on the acetylcholine content of rat brain. *Naunyn Schmiedebergs Arch Pharmacol* 1976; 295: 9–14.
167. Nava F, Carta G, Bortolato M, et al. gamma-Hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA(B) receptors. *Eur J Pharmacol* 2001; 430: 261–263.
168. Shefner SA, Osmanovic SS. GABAA and GABAB receptors and the ionic mechanisms mediating their effects on locus coeruleus neurons. *Prog Brain Res* 1991; 88: 187–195.
169. Persson B, Henning M. Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine

- and acetylcholine transmission. *Acta Pharmacol Toxicol* 1980; 47: 335–346.
170. Szabo ST, Gold MS, Goldberger BA, et al. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. *Biol Psychiatry* 2004; 55: 934–939.
171. Sleep Neurobiology for the Clinician. 2004; 1–10.
172. Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. *Can J Neurol Sci* 1980; 7: 23–31.
173. A Pilot Study on the Effects of Sodium Oxybate on Sleep Architecture and Daytime Alertness in Narcolepsy. 2004; 1–8.
174. Mamelak M Stokan O. EJM. The effects of gamma-hydroxybutyrate on sleep. . *Biol Psychiatry* 1977; 12: 273–288.
175. Xyrem. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. *Sleep* 2002; 25: 42–49.
176. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. *Sleep Med* 2004; 5: 119–123.
177. Grou USXM-CS. The Abrupt Cessation of Therapeutically Administered Sodium Oxybate (GHB) Does Not Cause Withdrawal Symptoms. *Clin Toxicol* 2003; 41: 131–135.
178. Galloway GP, Frederick-Osborne SL, Seymour R, et al. Abuse and therapeutic potential of gamma-hydroxybutyric acid. *Alcohol* 2000; 20: 263–269.
179. Ferraro L, Tanganelli S, O'Connor WT, et al. gamma-Hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. *J Neurochem* 2001; 78: 929–939.
180. Berton F, Brancucci A, Beghe F, et al. Gamma-Hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slices. *Eur J Pharmacol* 1999; 380: 109–116.
181. King MA, Thinschmidt JS, Walker DW. Gammahydroxybutyrate (GHB) receptor ligand effects on evoked synaptic field potentials in CA1 of the rat hippocampal slice. *J Neural Transm* 1997; 104: 1177–1193.
182. Banerjee PK, Snead 3rd OC. Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GH. *J Pharmacol Exp Ther* 1995; 273: 1534–1543.
183. Oyama T, Takiguchi M. Effects of gamma-hydroxybutyrate and surgery on plasma human growth hormone and insulin levels. *Agressologie* 1970; 11: 289–298.
184. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in

- normal young Men. *J Clin Invest* 1997; 100: 745–753.
185. Van Cauter E, Copinschi G. Interrelationships between growth hormone and sleep. *Growth Horm IGF Res* 2000; 10 Suppl B: S57-62.
 186. Gerra G, Caccavari R, Fontanesi B, et al. Flumazenil effects on growth hormone response to gamma-hydroxybutyric acid. *Int Clin Psychopharmacol* 1994; 9: 211–215.
 187. Volpi R, Chiodera P, Caffarra P, et al. Different control mechanisms of growth hormone (GH) secretion between gamma-amino- and gamma-hydroxy-butyrac acid: neuroendocrine evidence in Parkinson’s disease. *Psychoneuroendocrinology* 1997; 22: 531–538.
 188. Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*. 1998; 1–81.
 189. Volpi R, Chiodera P, Caffarra P, et al. Muscarinic cholinergic mediation of the GH response to gamma-hydroxybutyric acid: neuroendocrine evidence in normal and parkinsonian subjects. *Psychoneuroendocrinology* 2000; 25: 179–185.
 190. Overeem S, Kok SW, Lammers GJ, et al. Somatotrophic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. *Am J Physiol Metab* 2003; 284: E641–E647.
 191. Donjacour CEHM, Aziz NA, Roelfsema F, et al. The effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. *Am J Physiol Metab* 2011; 300: E1069–E1075.
 192. Barbaccia ML, Carai MA, Colombo G, et al. Endogenous gamma-aminobutyric acid (GABA)(A) receptor active neurosteroids and the sedative/hypnotic action of gamma-hydroxybutyric acid (GHB): a study in GHB-S (sensitive) and GHB-R (resistant) rat lines. *Neuropharmacology* 2005; 49: 48–58.
 193. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. *Physiol Rev* 2000; 80: 1523–1631.
 194. Bole-Feysot C, Goffin V, Ederly M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. *Endocr Rev* 1998; 19: 225–268.
 195. Carter LP, Koek W, France CP. Behavioral analyses of GHB: receptor mechanisms. *Pharmacol Ther* 2009; 121: 100–114.
 196. Donjacour CEHM, Aziz NA, Frölich M, et al. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. *Eur J Endocrinol* 2011; 164: 363–370.
 197. Zeitzer JM, Duffy JF, Lockley SW, et al. Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. *SLEEP-NEW YORK THEN WESTCHESTER-* 2007; 30: 1437.
 198. Reiter RJ, Tan D-X, Fuentes-Broto L. Melatonin: a multitasking molecule. *Prog Brain Res* 2010; 181: 127–151.
 199. Appelbaum L, Wang GX, Maro GS, et al. Sleep–wake regulation and hypocretin–melatonin interaction in zebrafish. *Proc Natl Acad Sci* 2009; 106: 21942–21947.

200. Donjacour CEHM, Kalsbeek A, Overeem S, et al. Altered circadian rhythm of melatonin concentrations in hypocretin-deficient men. *Chronobiol Int* 2012; 29: 356–362.
201. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. *Nature* 2000; 407: 908–913.
202. Hypothalamic Orexin Neurons Regulate Arousal According to Energy Balance in Mice. 2003; 1–14.
203. Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes* 2009; 58: 1509–1517.
204. Pimpin L, Wu JHY, Haskelberg H, et al. Is butter back? A systematic review and meta-analysis of butter consumption and risk of cardiovascular disease, diabetes, and total mortality. *PLoS One* 2016; 11: e0158118.
205. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2012; 143: 913–916. e7.
206. Hartstra A V, Bouter KEC, Bäckhed F, et al. Insights into the role of the microbiome in obesity and type 2 diabetes. *Diabetes Care* 2015; 38: 159–165.
207. Christensen DP, Dahllöf M, Lundh M, et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. *Mol Med* 2011; 17: 378.
208. Klein C, Kemmel V, Taleb O, et al. Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition. *Neuropharmacology* 2009; 57: 137–147.
209. Johannsson G, Mårin P, Lönn L, et al. Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure 1. *J Clin Endocrinol Metab* 1997; 82: 727–734.
210. Junnila RK, List EO, Berryman DE, et al. The GH/IGF-1 axis in ageing and longevity. *Nat Rev Endocrinol* 2013; 9: 366–376.
211. Donjacour CE, Aziz NA, Overeem S, et al. Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. *Sleep* 2014; 37: 795–801.
212. Saper CB, Lowell BB. The hypothalamus. *Curr Biol* 2014; 24: R1111–R1116.
213. Romeijn N, Raymann RJEM, Møst E, et al. Sleep, vigilance, and thermosensitivity. *Pflügers Arch J Physiol* 2012; 463: 169–176.
214. Kräuchi K, Cajochen C, Werth E, et al. Physiology: warm feet promote the rapid onset of sleep. *Nature* 1999; 401: 36–37.
215. Van Someren EJW. Mechanisms and functions of coupling between sleep and temperature rhythms. *Prog Brain Res* 2006; 153: 309–324.
216. Yetish G, Kaplan H, Gurven M, et al. Natural sleep and its seasonal variations in three pre-industrial societies. *Curr Biol* 2015; 25: 2862–2868.
217. Fronczek R, Overeem S, Lammers GJ, et al. Altered skin-temperature regulation in narcolepsy relates to sleep propensity. *Sleep* 2006; 29: 1444–

- 1449.
218. Van Someren EJW. Sleep propensity is modulated by circadian and behavior-induced changes in cutaneous temperature. *J Therm Biol* 2004; 29: 437–444.
 219. Kaufman EE, Porrino LJ, Nelson T. Pyretic action of low doses of gamma-hydroxybutyrate in rats. *Biochem Pharmacol* 1990; 40: 2637–2640.
 220. Spatz M, Abe K, Smialek M, et al. Evaluation of gamma-hydroxybutyrate treatment in experimental cerebral ischemia. In: *Pathophysiology and pharmacotherapy of cerebrovascular disorders*. Wilzrock Baden Baden, 1980, pp. 286–289.
 221. Yosunkaya A, Ak A, Bariskaner H, et al. Effect of gamma-hydroxybutyric acid on lipid peroxidation and tissue lactate level in experimental head trauma. *J Trauma* 2004; 56: 585–590.
 222. Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. *Ann Emerg Med* 1998; 31: 716–22.
 223. Krul J, Girbes ARJ. Gamma-hydroxybutyrate: Experience of 9 years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. *Clin Toxicol* 2011; 49: 311–315.
 224. Queva C, Bremner-Danielsen M, Edlund A, et al. Effects of GABA agonists on body temperature regulation in GABA(B(1))^{-/-} mice. *Br J Pharmacol* 2003; 140: 315–322.
 225. Lin MT, Chern YF, Wang HS, et al. Effects of gamma-hydroxybutyric acid on metabolic, respiratory and vasomotor activities and body temperature in rats. *J Pharmacol Exp Ther* 1979; 211: 167–170.
 226. van der Heide A, Werth E, Donjacour CE, et al. Core Body and Skin Temperature in Type 1 Narcolepsy in Daily Life; Effects of Sodium Oxybate and Prediction of Sleep Attacks. *Sleep* 2016; 39: 1941.
 227. Mease PJ, Clauw DJ, Christensen R, et al. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. *J Rheumatol Suppl* 2011; 38: 1487–1495.
 228. Russell IJ, Holman AJ, Swick TJ, et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. *Pain* 2011; 152: 1007–1017.
 229. Spaeth M, Bennett RM, Benson BA, et al. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. *Ann Rheum Dis* 2012; annrheumdis-2011-200418.
 230. Rechtschaffen A, Gilliland MA, Bergmann BM, et al. Physiological correlates of prolonged sleep deprivation in rats. *Science (80-)* 1983; 221: 182–184.
 231. Walsh JK, Hall-Porter JM, Griffin KS, et al. Enhancing slow wave sleep with sodium oxybate reduces the behavioral and physiological impact of sleep loss. *Sleep* 2010; 33: 1217–1225.
 232. McNay DEG, Speakman JR. High fat diet causes rebound weight gain. *Mol Metab* 2013; 2: 103–108.

233. Fisler JS, Shimizu H, Bray GA. Brain 3-hydroxybutyrate, glutamate, and GABA in a rat model of dietary obesity. *Physiol Behav* 1989; 45: 571–577.
234. Borbély AA, Huston JP. Effects of Gamma-Butyrolactone on Body Temperature and Evoked Potentials in the Rat1. In: *Sleep 1972*. Karger Publishers, 1973, p. 355a–359.
235. Jouvét M, Cier A, Mounier D, et al. [Effect of sodium 4-hydroxybutyrate and 4-butyrolactone on cat EEG and behavior.]. *C R Seances Soc Biol Fil* 1961; 155: 1313–1316.
236. Laborit H. Correlations between protein and serotonin synthesis during various activities of the central nervous system (slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness, and pharmacological action of sodium gam. *Res Commun Chem Pathol Pharmacol* 1972; 3: 51–81.
237. Godschalk M, Dzoljic MR, Bonta IL. Slow wave sleep and a state resembling absence epilepsy induced in the rat by gamma-hydroxybutyrate. *Eur J Pharmacol* 1977; 44: 105–111.
238. Winters WD, Spooner CE. Various Seizure Activities Following Gamma-Hydroxybutyrate. *Int J Neuropharmacol* 1965; 31: 197–200.
239. Marcus RJ, Winters WD, Mori K, et al. EEG and behavioral comparison of the effects of gamma-hydroxybutyrate, gamma-butyrolactone and short chain fatty acids in the rat. *Int J Neuropharmacol* 1967; 6: 175–185.
240. Bosch OG, Eisenegger C, Gertsch J, et al. Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. *Psychoneuroendocrinology* 2015; 62: 1–10.
241. Bosch OG, Havranek MM, Baumberger A, et al. Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans. *Eur Neuropsychopharmacol*.
242. Laborit H, Jouany JM, Gerard J, et al. [Generalities concerning the experimental study and clinical use of gamma hydroxybutyrate of Na.]. *Agressologie* 1960; 1: 397–406.
243. Laborit H, Jouany JM, Gerard J, et al. [Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate.]. *Press Med* 1960; 68: 1867–1869.
244. Laborit H, Buchard F, Laborit G, et al. [Use of sodium 4-hydroxybutyrate in anesthesia and resuscitation.]. *Agressologie* 1960; 1: 549–560.
245. Jouany JM, Gerard J, Weber B, et al. [Interference of various pharmacological agents with the establishment and character of sleep induced by 4-hydroxybutyric acid.]. *Agressologie* 1961; 2: 45–47.
246. Reder Mednick AS, Brown P, Spire JP, Van Cauter E, Wollmann RL, Cervenakova L, Goldfarb LG, Garay A, Ovsiew F, et al. AT. Clinical and genetic studies of fatal familial insomnia. . *Neurology* 1995; 45: 1068–1075.
247. Moldofsky H. Sleep and musculoskeletal pain. *Am J Med* 1986; 81: 85–89.
248. Moldofsky H, Scarisbrick P, England R, et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with ‘fibrositis syndrome’ and healthy subjects. *Psychosom Med* 1975; 37: 341–351.

249. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. *J Rheumatol* 1999; 26: 1586–1592.
250. Moldofsky H, Inhaber NH, Guinta DR, et al. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. *J Rheumatol* 2010; 37: 2156–2166.
251. Russell IJ, Perkins AT, Michalek JE, et al. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. *Arthritis Rheum* 2009; 60: 299–309.
252. Roizenblatt S, Moldofsky H, Benedito-Silva AA, et al. Alpha sleep characteristics in fibromyalgia. *Arthritis Rheum* 2001; 44: 222–230.
253. Vijayan S, Klerman EB, Adler GK, et al. Thalamic mechanisms underlying alpha-delta sleep with implications for fibromyalgia. *J Neurophysiol* 2015; 114: 1923–1930.
254. Rye DB, Bliwise DL, Dihenia B, et al. FAST TRACK: daytime sleepiness in Parkinson’s disease. *J Sleep Res* 2000; 9: 63–69.
255. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. *Neurology* 2002; 58: 341–346.
256. Ondo WG, Perkins T, Swick T, et al. Nocturnal sodium oxybate for daytime sedation and fatigue in Parkinson’s disease, a polysomnogram trial. *World Congress of Movement Disorders*.
257. Burns A, Iliffe S. Alzheimer’s disease. *BMJ* 2009; 338: b158.
258. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. IV: Disorders of behaviour. *Br J Psychiatry* 1990; 157: 86–94.
259. Maitre M, Klein C, Mensah-Nyagan AG. A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer’s disease. *Alzheimers Res Ther* 2016; 8: 37.
260. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS β -amyloid in Alzheimer’s disease. *Science (80-)* 2010; 330: 1774.
261. Miners JS, Barua N, Kehoe PG, et al. A β -degrading enzymes: potential for treatment of Alzheimer disease. *J Neuropathol Exp Neurol* 2011; 70: 944–959.
262. Nalivaeva NN, Beckett C, Belyaev ND, et al. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? *J Neurochem* 2012; 120: 167–185.
263. Mamelak M. Alzheimer’s disease, oxidative stress and gammahydroxybutyrate. *Neurobiol Aging* 2007; 28: 1340–1360.
264. Klein C, Mathis C, Leva G, et al. γ -Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer’s disease. *Neurobiol Aging* 2015; 36: 832–844.
265. Guarnieri B, Adorni F, Musicco M, et al. Prevalence of Sleep Disturbances in Mild Cognitive Impairment and Dementing Disorders: A Multicenter Italian Clinical Cross-Sectional Study on 431 Patients. *Dement Geriatr Cogn*

- Disord* 2012; 33: 50–58.
266. Hita-Yanez E, Atienza M, Gil-Neciga E, et al. Disturbed Sleep Patterns in Elders with Mild Cognitive Impairment: The Role of Memory Decline and ApoE ϵ 4 Genotype. *Curr Alzheimer Res* 2012; 9: 290–297.
 267. Osorio RS, Pirraglia E, Agüera-Ortiz LF, et al. Greater risk of Alzheimer’s disease in older adults with insomnia. *J Am Geriatr Soc* 2011; 59: 559–62.
 268. Osorio RS, Gumb T, Pirraglia E, et al. Sleep-disordered breathing advances cognitive decline in the elderly. *Neurology* 2015; 84: 1964–1971.
 269. Lim ASP, Kowgier M, Yu L, et al. Sleep Fragmentation and the Risk of Incident Alzheimer’s Disease and Cognitive Decline in Older Persons. *Sleep* 2013; 36: 1027–1032.
 270. Ancoli-Israel S, Palmer BW, Cooke JR, et al. Cognitive Effects of Treating Obstructive Sleep Apnea in Alzheimer’s Disease: A Randomized Controlled Study. *J Am Geriatr Soc* 2008; 56: 2076–2081.
 271. Liguori C, Romigi A, Nuccetelli M, et al. Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. *JAMA Neurol* 2014; 71: 1498.
 272. Mander BA, Marks SM, Vogel JW, et al. β -amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. *Nat Neurosci* 2015; 18: 1051–1057.
 273. Sprecher KE, Bendlin BB, Racine AM, et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. *Neurobiol Aging* 2015; 36: 2568–2576.
 274. Ancoli-Israel S, Klauber MR, Butters N, et al. Dementia in Institutionalized Elderly: Relation to Sleep Apnea. *J Am Geriatr Soc* 1991; 39: 258–263.
 275. Prinz PN, Vitaliano PP, Vitiello M V., et al. Sleep, EEG and mental function changes in senile dementia of the Alzheimer’s type. *Neurobiol Aging* 1982; 3: 361–370.
 276. Kang J-E, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. *Science* 2009; 326: 1005–7.
 277. Roh JH, Huang Y, Bero AW, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of β -amyloid in mice with Alzheimer’s disease pathology. *Sci Transl Med* 2012; 4: 150ra122.
 278. Xie L, Kang H, Xu Q, et al. Sleep Drives Metabolite Clearance from the Adult Brain. *Science (80-)* 2013; 342: 373–377.
 279. Ju Y-ES, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology—a bidirectional relationship. *Nat Rev Neurol* 2013; 10: 115–119.
 280. Everson CA, Henchen CJ, Szabo A, et al. Cell Injury and Repair Resulting from Sleep Loss and Sleep Recovery in Laboratory Rats. *Sleep* 2014; 37: 1929–1940.
 281. Villafuerte G, Miguel-Puga A, Murillo Rodríguez E, et al. Sleep Deprivation and Oxidative Stress in Animal Models: A Systematic Review. *Oxid Med Cell Longev* 2015; 2015: 1–15.
 282. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative Stress Induces

- Intracellular Accumulation of Amyloid β -Protein (A β) in Human Neuroblastoma Cells. *Biochemistry* 2000; 39: 6951–6959.
283. Yatin SM, Varadarajan S, Link CD, et al. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). *Neurobiol Aging* 1999; 20: 325-30-42.
284. Kurup P, Zhang Y, Xu J, et al. A -Mediated NMDA Receptor Endocytosis in Alzheimer's Disease Involves Ubiquitination of the Tyrosine Phosphatase STEP61. *J Neurosci* 2010; 30: 5948–5957.
285. Steriade M, Nuñez A, Amzica F. A novel slow (< 1 Hz) oscillation of neocortical neurons in vivo: depolarizing and hyperpolarizing components. *J Neurosci* 1993; 13: 3252–65.
286. Mander BA, Winer JR, Jagust WJ, et al. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? *Trends Neurosci* 2016; 39: 552–566.
287. Kaestner EJ, Wixted JT, Mednick SC. Pharmacologically Increasing Sleep Spindles Enhances Recognition for Negative and High-arousal Memories. *J Cogn Neurosci* 2013; 25: 1597–1610.
288. Maitre M, Klein C, Mensah-Nyagan AG. Mechanisms for the Specific Properties of γ -Hydroxybutyrate in Brain. *Med Res Rev* 2016; 36: 363–388.
289. Busche MA, Kekuš M, Adelsberger H, et al. Rescue of long-range circuit dysfunction in Alzheimer's disease models. *Nat Neurosci* 2015; 18: 1623–1630.
290. Broughton and Mamelak M. R. *Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report. I.* Spectrum, New York., 1976.
291. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. *Can J Neurol Sci* 1979; 6: 1–6.
292. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. *Sleep* 1986; 9: 285–289.
293. Scharf MB, Brown D, Woods M, et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. *J Clin Psychiatry* 1985; 46: 222–225.
294. Scrima L, Hartman PG, Johnson Jr. FH, et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. *Biol Psychiatry* 1989; 26: 331–343.
295. Lammers GJ, Arends J, Declerck AC, et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. *Sleep* 1993; 16: 216–220.
296. Scrima L, Hartman PG, Johnson Jr. FH, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. *Sleep* 1990; 13: 479–490.
297. Group USXMS. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. *Sleep* 2003; 26: 31–35.

298. A Double-Blind, Placebo-Controlled Study Demonstrates Sodium Oxybate Is Effective for the Treatment of Excessive Daytime Sleepiness in Narcolepsy. 2005; 1–7.
299. Sodium Oxybate Improves Excessive Daytime Sleepiness in Narcolepsy. 2006; 1–8.
300. Blundell JE, Gillett A. Control of food intake in the obese. *Obes Res* 2001; 9 Suppl 4: 263S–270S.
301. Blundell JE, Goodson S, Halford JC. Regulation of appetite: role of leptin in signalling systems for drive and satiety. *Int J Obes Relat Metab Disord* 2001; 25 Suppl 1: S29–34.
302. Saper CB. Staying awake for dinner: hypothalamic integration of sleep, feeding, and circadian rhythms. *Prog Brain Res* 2006; 153: 243–252.
303. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. *Cell* 2001; 104: 531–543.
304. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. *Int J Obes Relat Metab Disord* 1998; 22: 39–47.
305. Prevalence and Trends in Obesity Among US Adults, 1999–2008. 2010; 1–8.
306. BRFSS. BRFSS, Behavioral Risk Factor Surveillance System <http://www.cdc.gov/brfss/> (2010).
307. *Vital Signs: State-Specific Obesity Prevalence Among Adults —United States 2009*. 2010.
308. Fontaine KR, Barofsky I. Obesity and health-related quality of life. *Obes Rev* 2001; 2: 173–182.
309. Flegal KM. Estimating the impact of obesity. *Soz Praventivmed* 2005; 50: 73–74.
310. Flegal KM, Graubard BI, Williamson DF, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. *JAMA* 2007; 298: 2028–2037.
311. Flegal KM, Williamson DF, Graubard BI. Obesity and cancer. *N Engl J Med* 2003; 349: 502–504.
312. Maiese DR. Healthy people 2010—leading health indicators for women. *Womens Heal Issues* 2002; 12: 155–164.
313. Cai L, Lubitz J, Flegal KM, et al. The predicted effects of chronic obesity in middle age on medicare costs and mortality. *Med Care* 2010; 48: 510–517.
314. Stein CJ, Colditz GA. The epidemic of obesity. *J Clin Endocrinol Metab* 2004; 89: 2522–2525.
315. Hill JO, Wyatt HR, Reed GW, et al. Obesity and the environment: where do we go from here? *Science (80-)* 2003; 299: 853–855.
316. World Health Organization. *Obesity: Preventing and Managing the Global Epidemic*. Geneva, Switzerland: World Health Organization, 2000.
317. Chaput JP, Leblanc C, Perusse L, et al. Risk factors for adult overweight and obesity in the Quebec Family Study: have we been barking up the wrong

- tree? *Obes (Silver Spring)* 2009; 17: 1964–1970.
318. Magee CA, Iverson DC, Huang XF, et al. A link between chronic sleep restriction and obesity: methodological considerations. *Public Health* 2008; 122: 1373–1381.
 319. Obesity and Sleep: A Bidirectional Association? 2010; 1–2.
 320. Ogden CL, Yanovski SZ, Carroll MD, et al. The epidemiology of obesity. *Gastroenterology* 2007; 132: 2087–2102.
 321. Spiegel K, Tasali E, Penev P, et al. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. *Ann Intern Med* 2004; 141: 846–850.
 322. 2005 ‘Sleep in America’ Poll <http://www.sleepfoundation.org/product.nsf-2005-sleep-america-poll> (2005).
 323. Lauderdale DS, Knutson KL, Rathouz PJ, et al. Cross-sectional and Longitudinal Associations Between Objectively Measured Sleep Duration and Body Mass Index: The CARDIA Sleep Study. *Am J Epidemiol* 2009; 170: 805–813.
 324. Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med* 2004; 1: e62.
 325. Kripke DF, Garfinkel L, Wingard DL, et al. Mortality associated with sleep duration and insomnia. *Arch Gen Psychiatry* 2002; 59: 131–136.
 326. Foundation NS. "Sleep in America" Poll.
 327. Foundation NS. Sleep for America Poll. *Summ Find*.
 328. Knutson KL, Spiegel K, Penev P, et al. The metabolic consequences of sleep deprivation. *Sleep Med Rev* 2007; 11: 163–178.
 329. Locard E, Mamelle N, Billette A, et al. Risk factors of obesity in a five year old population. Parental versus environmental factors. *Int J Obes Relat Metab Disord* 1992; 16: 721–729.
 330. Vioque J, Torres A, Quiles J. Time spent watching television, sleep duration and obesity in adults living in Valencia, Spain. *Int J Obes Relat Metab Disord* 2000; 24: 1683–1688.
 331. von Kries R, Toschke AM, Wurmser H, et al. Reduced risk for overweight and obesity in 5- and 6-y-old children by duration of sleep--a cross-sectional study. *Int J Obes Relat Metab Disord* 2002; 26: 710–716.
 332. Gupta NK, Mueller WH, Chan W, et al. Is obesity associated with poor sleep quality in adolescents? *Am J Hum Biol* 2002; 14: 762–768.
 333. Hasler G, Buysse DJ, Klaghofer R, et al. The association between short sleep duration and obesity in young adults: a 13-year prospective study. *Sleep* 2004; 27: 661–666.
 334. Heslop P, Smith GD, Metcalfe C, et al. Sleep duration and mortality: The effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. *Sleep Med* 2002; 3: 305–314.
 335. Park SE, Kim HM, Kim DH, et al. The association between sleep duration

- and general and abdominal obesity in Koreans: data from the Korean National Health and Nutrition Examination Survey, 2001 and 2005. *Obesity* 2009; 17: 767–771.
336. Taheri S. The link between short sleep duration and obesity: we should recommend more sleep to prevent obesity. *Arch Dis Child* 2006; 91: 881–884.
 337. Gangwisch JE, Malaspina D, Boden-Albala B, et al. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. *Sleep* 2005; 28: 1289–1296.
 338. Cappuccio FP, Taggart FM, Kandala NB, et al. Meta-analysis of short sleep duration and obesity in children and adults. *Sleep* 2008; 31: 619–626.
 339. Patel SR, Blackwell T, Redline S, et al. The association between sleep duration and obesity in older adults. *Int J Obes* 2008; 32: 1825–1834.
 340. Association of Short Sleep Duration with Weight Gain and Obesity at 1-Year Follow-Up: A Large-Scale Prospective Study. 2010; 1–10.
 341. A Twin Study of Sleep Duration and Body Mass Index. 2010; 1–7.
 342. Associations Between Sleep Duration Patterns and Overweight/Obesity at Age 6. 2008; 1–8.
 343. Padez C, Mourao I, Moreira P, et al. Long sleep duration and childhood overweight/obesity and body fat. *Am J Hum Biol* 2009; 21: 371–376.
 344. Ozturk A, Mazicioglu MM, Poyrazoglu S, et al. The relationship between sleep duration and obesity in Turkish children and adolescents. *Acta Paediatr* 2009; 98: 699–702.
 345. Knutson KL, Lauderdale DS. Sleep Duration and Overweight in Adolescents: Self-reported Sleep Hours Versus Time Diaries. *Pediatrics* 2007; 119: e1056–e1062.
 346. Danielsen Y, Pallesen S, Stormark K, et al. The relationship between school day sleep duration and body mass index in Norwegian children (aged 10–12). *Int J Pediatr Obes* 2010; 5: 214–220.
 347. Shortened Nighttime Sleep Duration in Early Life and Subsequent Childhood Obesity. 2010; 1–6.
 348. Nielsen LS, Danielsen K V, Sørensen TIA. Short sleep duration as a possible cause of obesity: critical analysis of the epidemiological evidence. *Obes Rev* 2011; 12: 78–92.
 349. Van Den Berg JF, Neven AK, Tulen JHM, et al. Actigraphic sleep duration and fragmentation are related to obesity in the elderly: the Rotterdam Study. *Int J Obes* 2008; 32: 1083–1090.
 350. Patel SR, Ayas NT, Malhotra MR, et al. A prospective study of sleep duration and mortality risk in women. *Sleep* 2004; 27: 440–444.
 351. Theorell-Haglow J, Berne C, Janson C, et al. Associations between short sleep duration and central obesity in women. *Sleep* 2010; 33: 593–598.
 352. Hart CN, Carskadon MA, Considine R V, et al. Changes in children’s sleep duration on food intake, weight, and leptin. *Pediatrics* 2013; 132: e1473–80.

353. Association of Sleep Time With Diabetes Mellitus and Impaired Glucose Tolerance. 2005; 1–6.
354. Shin C, Kim J, Lee S, et al. Association of habitual snoring with glucose and insulin metabolism in nonobese Korean adult men. *Am J Respir Crit Care Med* 2005; 171: 287–291.
355. Elmasry A, Janson C, Lindberg E, et al. The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population. *J Intern Med* 2000; 248: 13–20.
356. Al-Delaimy WK, Manson JE, Willett WC, et al. Snoring as a risk factor for type II diabetes mellitus: a prospective study. *Am J Epidemiol* 2002; 155: 387–393.
357. Donga E, van Dijk M, van Dijk JG, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. *J Clin Endocrinol Metab* 2010; 95: 2963–2968.
358. Donga E, van Dijk M, van Dijk JG, et al. Partial sleep restriction decreases insulin sensitivity in type 1 diabetes. *Diabetes Care* 2010; 33: 1573–1577.
359. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. *Endocr Rev* 1997; 18: 716–738.
360. Barf RP, Meerlo P, Scheurink AJ. Chronic sleep disturbance impairs glucose homeostasis in rats. *Int J Endocrinol* 2010; 2010: 819414.
361. Slow-wave sleep and the risk of type 2 diabetes in humans. 2008; 1–6.
362. Herzog N, Jauch-Chara K, Hyzy F, et al. Selective slow wave sleep but not rapid eye movement sleep suppression impairs morning glucose tolerance in healthy men. *Psychoneuroendocrinology* 2013; 38: 2075–2082.
363. Broussard J, Brady MJ. The impact of sleep disturbances on adipocyte function and lipid metabolism. *Best Pract Res Clin Endocrinol Metab* 2010; 24: 763–773.
364. Broussard J, Day A, Brady M, et al. Experimental Reduction on Sleep Duration or Quality is Associated with Impaired Insulin Signaling in the Adipocyte. *Sleep; Suppl*.
365. Chaput JP, Despres JP, Bouchard C, et al. Association of sleep duration with type 2 diabetes and impaired glucose tolerance. *Diabetologia* 2007; 50: 2298–2304.
366. Chaput JP, Tremblay A. The glucostatic theory of appetite control and the risk of obesity and diabetes. *Int J Obes* 2009; 33: 46–53.
367. Boule NG, Chaput JP, Doucet E, et al. Glucose homeostasis predicts weight gain: prospective and clinical evidence. *Diabetes Metab Res Rev* 2008; 24: 123–129.
368. Skuladottir GV, Nilsson EK, Mwinyi J, et al. One-night sleep deprivation induces changes in the DNA methylation and serum activity indices of stearoyl-CoA desaturase in young healthy men. *Lipids Health Dis* 2016; 15: 137.
369. Martins PJ, Marques MS, Tufik S, et al. Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation. *Am J Physiol Endocrinol Metab* 2010; 298:

- E726-34.
370. Galvao Mde O, Sinigaglia-Coimbra R, Kawakami SE, et al. Paradoxical sleep deprivation activates hypothalamic nuclei that regulate food intake and stress response. *Psychoneuroendocrinology* 2009; 34: 1176–1183.
 371. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? *Obes Rev* 2001; 2: 73–86.
 372. Bjorntorp P, Rosmond R. Obesity and cortisol. *Nutrition* 2000; 16: 924–936.
 373. Schmid SM, Jauch-Chara K, Hallschmid M, et al. Mild sleep restriction acutely reduces plasma glucagon levels in healthy men. *J Clin Endocrinol Metab* 2009; 94: 5169–5173.
 374. Guyon A, Morselli LL, Balbo ML, et al. Effects of Insufficient Sleep on Pituitary-Adrenocortical Response to CRH Stimulation in Healthy Men. *Sleep*.
 375. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. *Nature* 1996; 382: 250–252.
 376. Spiegel K, Leproult R, L'Hermite-Baleriaux M, et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. *J Clin Endocrinol Metab* 2004; 89: 5762–5771.
 377. Licinio J, Mantzoros C, Negrao AB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. *Nat Med* 1997; 3: 575–579.
 378. Chaput JP, Despres JP, Bouchard C, et al. Short sleep duration is associated with reduced leptin levels and increased adiposity: Results from the Quebec family study. *Obes (Silver Spring)* 2007; 15: 253–261.
 379. Yin X, Li Y, Xu G, et al. Ghrelin fluctuation, what determines its production? *Acta Biochim Biophys Sin* 2009; 41: 188–197.
 380. Hosoda H, Kangawa K. The autonomic nervous system regulates gastric ghrelin secretion in rats. *Regul Pept* 2008; 146: 12–18.
 381. Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. *Biochem Biophys Res Commun* 2001; 281: 1220–1225.
 382. Dzaja A, Dalal MA, Himmerich H, et al. Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. *Am J Physiol Endocrinol Metab* 2004; 286: E963-7.
 383. Sleep Loss Reduces Diurnal Rhythm Amplitude of Leptin in Healthy Men. 2003; 1–4.
 384. Nedeltcheva A, Kilkus J, Imperial J, et al. Sleep restriction can compromise the beneficial effect of diet-induced weight loss on total body adiposity. In: David F. Dinges P (ed) *Associated Professional Sleep Societies (APSS)*. Seattle, WA: SLEEP, 2009, p. A126.
 385. Schmid SM, Hallschmid M, Jauch-Chara K, et al. Short-term sleep loss decreases physical activity under free-living conditions but does not increase food intake under time-deprived laboratory conditions in healthy

- men. *Am J Clin Nutr* 2009; 90: 1476–1482.
386. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature* 2001; 410: 822–825.
387. Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. *PLoS One* 2008; 3: e1797.
388. Cota D, Tschöp MH, Horvath TL, et al. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? *Brain Res Rev* 2006; 51: 85–107.
389. Melis T, Succu S, Sanna F, et al. The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. *Neurosci Lett* 2007; 419: 231–235.
390. Kirkham TC, Williams CM, Fezza F, et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. *Br J Pharmacol* 2002; 136: 550–557.
391. De Luca MA, Solinas M, Bimpisidis Z, et al. Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. *Neuropharmacology* 2012; 63: 161–168.
392. Hanlon EC, Tasali E, Leproult R, et al. Sleep restriction enhances the daily rhythm of circulating levels of endocannabinoid 2-arachidonoylglycerol. *Sleep* 2016; 39: 653–664.
393. Liukkonen T, Rasanen P, Ruokonen A, et al. C-reactive protein levels and sleep disturbances: observations based on the Northern Finland 1966 Birth Cohort study. *Psychosom Med* 2007; 69: 756–761.
394. Irwin MR, Wang M, Campomayor CO, et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. *Arch Intern Med* 2006; 166: 1756–1762.
395. Irwin MR, Olmstead R, Valladares EM, et al. Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. *Biol Psychiatry* 2009; 66: 191–195.
396. Rolland YM, Perry 3rd HM, Patrick P, et al. Leptin and adiponectin levels in middle-aged postmenopausal women: associations with lifestyle habits, hormones, and inflammatory markers--a cross-sectional study. *Metabolism* 2006; 55: 1630–1636.
397. Zheng H, Patel M, Hryniewicz K, et al. Association of extended work shifts, vascular function, and inflammatory markers in internal medicine residents: a randomized crossover trial. *JAMA* 2006; 296: 1049–1050.
398. Vgontzas AN, Zoumaki M, Bixler EO, et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. *J Clin Endocrinol Metab* 2003; 88: 2087–2095.
399. Ravussin E, Lillioja S, Anderson TE, et al. Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. *J*

- Clin Invest* 1986; 78: 1568–1578.
400. Brondel L, Romer MA, Nougues PM, et al. Acute partial sleep deprivation increases food intake in healthy men. *Am J Clin Nutr* 2010; 91: 1550–1559.
 401. Weinert D, Waterhouse J. The circadian rhythm of core temperature: effects of physical activity and aging. *Physiol Behav* 2007; 90: 246–256.
 402. Landsberg L, Young JB, Leonard WR, et al. Do the obese have lower body temperatures? A new look at a forgotten variable in energy balance. *Trans Am Clin Clim Assoc* 2009; 120: 287–295.
 403. Landsberg L, Young JB, Leonard WR, et al. Is obesity associated with lower body temperatures? Core temperature: a forgotten variable in energy balance. *Metabolism* 2009; 58: 871–876.
 404. Nedeltcheva A V, Kessler L, Imperial J, et al. Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. *J Clin Endocrinol Metab* 2009; 94: 3242–3250.
 405. Albrecht U, Eichele G. The mammalian circadian clock. *Curr Opin Genet Dev* 2003; 13: 271–277.
 406. Zanutta MM, Correa-Giannella ML, Monteiro MB, et al. Body weight, metabolism and clock genes. *Diabetol Metab Syndr* 2010; 2: 53.
 407. Ekmekcioglu C, Touitou Y. Chronobiological aspects of food intake and metabolism and their relevance on energy balance and weight regulation. *Obes Rev* 2010; 12: 14–25.
 408. Arble DM, Bass J, Laposky AD, et al. Circadian timing of food intake contributes to weight gain. *Obesity* 2009; 17: 2100–2102.
 409. Kohsaka A, Laposky AD, Ramsey KM, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. *Cell Metab* 2007; 6: 414–421.
 410. Turek FW, Joshu C, Kohsaka A, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. *Science (80-)* 2005; 308: 1043–1045.
 411. Biggi N, Consonni D, Galluzzo V, et al. Metabolic syndrome in permanent night workers. *Chronobiol Int* 2008; 25: 443–454.
 412. Esquirol Y, Bongard V, Mabile L, et al. Shift work and metabolic syndrome: respective impacts of job strain, physical activity, and dietary rhythms. *Chronobiol Int* 2009; 26: 544–559.
 413. Karlsson B, Knutsson A, Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. *Occup Env Med* 2001; 58: 747–752.
 414. Tasali E, Broussard J, Day A, et al. Sleep curtailment in healthy young adults is associated with increased ad lid food intake. *Sleep*.
 415. Calvin AD, Carter RE, Adachi T, et al. Effects of experimental sleep restriction on caloric intake and activity energy expenditure. *Chest* 2013; 144: 79–86.
 416. Spaeth AM, Dinges DF, Goel N. Effects of Experimental Sleep Restriction on Weight Gain, Caloric Intake, and Meal Timing in Healthy Adults. *Sleep* 2013; 36: 981–990.

417. Markwald RR, Melanson EL, Smith MR, et al. Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain. *Proc Natl Acad Sci U S A* 2013; 110: 5695–5700.
418. Hogenkamp PS, Nilsson E, Nilsson VC, et al. Acute sleep deprivation increases portion size and affects food choice in young men. *Psychoneuroendocrinology* 2013; 38: 1668–1674.
419. Chapman CD, Nilsson EK, Nilsson VC, et al. Acute sleep deprivation increases food purchasing in men. *Obes (Silver Spring)* 2013; 21: E555-60.
420. Borbély AA. A two process model of sleep regulation. *Hum Neurobiol* 1982; 1: 195.
421. Van Dongen HPA, Dinges DF. Sleep, circadian rhythms, and psychomotor vigilance. *Clin Sport Med* 2005; 24: 237–249.
422. Van Dongen HPA, Rogers NL, Dinges DF. Understanding sleep debt: theoretical and empirical issues. *Sleep Biol Rhythm* 2003; 1: 4–12.
423. Belenky G, Wesensten NJ, Thorne DR, et al. Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. *J Sleep Res* 2003; 12: 1–12.
424. Van Dongen HP, Maislin G, Mullington JM, et al. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. *Sleep* 2003; 26: 117–126.
425. Harrison Y, Horne JA. Sleep loss and temporal memory. *Q J Exp Psychol A* 2000; 53: 271–279.
426. Chee MW, Chuah LY, Venkatraman V, et al. Functional imaging of working memory following normal sleep and after 24 and 35 h of sleep deprivation: Correlations of fronto-parietal activation with performance. *Neuroimage* 2006; 31: 419–428.
427. Chee MW, Choo WC. Functional imaging of working memory after 24 hr of total sleep deprivation. *J Neurosci* 2004; 24: 4560–4567.
428. Thomas M, Sing H, Belenky G, et al. Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. *J Sleep Res* 2000; 9: 335–352.
429. Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night. *Sleep* 1997; 20: 267–277.
430. Drummond SP, Brown GG. The effects of total sleep deprivation on cerebral responses to cognitive performance. *Neuropsychopharmacology* 2001; 25: S68-73.
431. Drummond SP, Gillin JC, Brown GG. Increased cerebral response during a divided attention task following sleep deprivation. *J Sleep Res* 2001; 10: 85–92.
432. Drummond SP, Brown GG, Gillin JC, et al. Altered brain response to verbal learning following sleep deprivation. *Nature* 2000; 403: 655–657.
433. Drummond SP, Brown GG, Salamat JS, et al. Increasing task difficulty

- facilitates the cerebral compensatory response to total sleep deprivation. *Sleep* 2004; 27: 445–451.
434. Drummond SP, Brown GG, Stricker JL, et al. Sleep deprivation-induced reduction in cortical functional response to serial subtraction. *Neuroreport* 1999; 10: 3745–3748.
435. Drummond SP, Meloy MJ, Yanagi MA, et al. Compensatory recruitment after sleep deprivation and the relationship with performance. *Psychiatry Res* 2005; 140: 211–223.
436. Drummond SP, Paulus MP, Tapert SF. Effects of two nights sleep deprivation and two nights recovery sleep on response inhibition. *J Sleep Res* 2006; 15: 261–265.
437. McKenna JT, Tartar JL, Ward CP, et al. Sleep fragmentation elevates behavioral, electrographic and neurochemical measures of sleepiness. *Neuroscience* 2007; 146: 1462–1473.
438. Stricker JL, Brown GG, Wetherell LA, et al. The impact of sleep deprivation and task difficulty on networks of fMRI brain response. *J Int Neuropsychol Soc* 2006; 12: 591–597.
439. Chee MW, Chuah YM. Functional neuroimaging and behavioral correlates of capacity decline in visual short-term memory after sleep deprivation. *Proc Natl Acad Sci U S A* 2007; 104: 9487–9492.
440. Turner TH, Drummond SP, Salamat JS, et al. Effects of 42 hr of total sleep deprivation on component processes of verbal working memory. *Neuropsychology* 2007; 21: 787–795.
441. Cote KA, Milner CE, Smith BA, et al. CNS arousal and neurobehavioral performance in a short-term sleep restriction paradigm. *J Sleep Res* 2009; 18: 291–303.
442. Franzen PL, Buysse DJ, Dahl RE, et al. Sleep deprivation alters pupillary reactivity to emotional stimuli in healthy young adults. *Biol Psychol* 2009; 80: 300–305.
443. Mu Q, Mishory A, Johnson KA, et al. Decreased brain activation during a working memory task at rested baseline is associated with vulnerability to sleep deprivation. *Sleep* 2005; 28: 433–446.
444. Banks S, Catcheside P, Lack L, et al. Low levels of alcohol impair driving simulator performance and reduce perception of crash risk in partially sleep deprived subjects. *Sleep* 2004; 27: 1063–1067.
445. Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. *J Clin Sleep Med* 2007; 3: 519–528.
446. Leproult R, Colecchia EF, Berardi AM, et al. Individual differences in subjective and objective alertness during sleep deprivation are stable and unrelated. *Am J Physiol Regul Integr Comp Physiol* 2003; 284: 280.
447. Van Dongen HP. Brain activation patterns and individual differences in working memory impairment during sleep deprivation. *Sleep* 2005; 28: 386–388.
448. Russo M, Thomas M, Thorne D, et al. Oculomotor impairment during chronic partial sleep deprivation. *Clin Neurophysiol* 2003; 114: 723–736.

449. Doran SM, Van Dongen HP, Dinges DF. Sustained attention performance during sleep deprivation: evidence of state instability. *Arch Ital Biol* 2001; 139: 253–267.
450. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. *Semin Neurol* 2005; 25: 117–129.
451. Mollicone DJ, Van Dongen H, Rogers NL, et al. Time of Day Effects on Neurobehavioral Performance During Chronic Sleep Restriction. *Aviat Space Environ Med* 2010; 81: 735–744.
452. Brunner DP, Dijk DJ, Borbely AA. Repeated partial sleep deprivation progressively changes in EEG during sleep and wakefulness. *Sleep* 1993; 16: 100–113.
453. Guilleminault C, Powell NB, Martinez S, et al. Preliminary observations on the effects of sleep time in a sleep restriction paradigm. *Sleep Med* 2003; 4: 177–184.
454. Neurobehavioral Dynamics Following Chronic Sleep Restriction: Dose-Response Effects of One Night for Recovery. 2010; 1–17.
455. Ratcliff R, Van Dongen H. Sleep deprivation affects multiple distinct cognitive processes. *Psychon Bull Rev* 2009; 16: 742.
456. The Executive Functions and Self-Regulation: An Evolutionary Neuropsychological Perspective. 2001; 1–29.
457. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. *Psychol Bull* 1997; 121: 65.
458. Overtom C. Employability skills: An update. *ERIC Dig*; 220.
459. Green L, Myerson J, Lichtman D, et al. Temporal discounting in choice between delayed rewards: The role of age and income. *Psychol Aging* 1996; 11: 79–84.
460. Schuck SEB, Crinella FM. Why children with ADHD do not have low IQs. *J Learn Disabil* 2005; 38: 262.
461. Bechara A. Decision making, impulse control and loss of willpower to resist drugs: A neurocognitive perspective. *Nature Neuroscience* 2005; 8: 1458–1463.
462. Johnson A, van der Meer MAA, Redish AD. Integrating hippocampus and striatum in decision-making. *Curr Opin Neurobiol* 2007; 17: 692–697.
463. Common regions of the human frontal lobe recruited by diverse cognitive demands. 2000; 1–9.
464. Harrison Y, Horne JA. The Impact of Sleep Deprivation of Decision Making: A Review. *J Exp Psychol Appl* 2000; 6: 236–249.
465. Chuah YML, Venkatraman V, Dinges DF, et al. The Neural Basis of Interindividual Variability in Inhibitory Efficiency after Sleep Deprivation. *J Neurosci* 2006; 26: 7156–7162.
466. Binks PG, Waters WF, Hurry M. Short-term total sleep deprivations does not selectively impair higher cortical functioning. *Sleep* 1999; 22: 328.
467. Choo WC, Lee WW, Venkatraman V, et al. Dissociation of cortical regions

- modulated by both working memory load and sleep deprivation and by sleep deprivation alone. *Neuroimage* 2005; 25: 579–587.
468. Gottselig JM, Adam M, Rétey J V, et al. Random number generation during sleep deprivation: effects of caffeine on response maintenance and stereotypy. *J Sleep Res* 2006; 15: 31–40.
469. Habeck C, Rakitin BC, Moeller J, et al. An event-related fMRI study of the neurobehavioral impact of sleep deprivation on performance of a delayed-match-to-sample task. *Cogn Brain Res* 2004; 18: 306–321.
470. Heuer H, Kohlisch O, Klein W. The effects of total sleep deprivation on the generation of random sequences of key-presses, numbers and nouns. *Q J Exp Psychol Sect A* 2005; 58: 275–307.
471. Jennings JR, Monk TH, Van der Molen MW. Sleep deprivation influences some but not all processes of supervisory attention. *Psychol Sci* 2003; 14: 473.
472. Killgore WDS, Balkin TJ, Wesensten NJ. Impaired decision making following 49 h of sleep deprivation. *J Sleep Res* 2006; 15: 7–13.
473. The effects of one night of sleep deprivation on known-risk and ambiguous-risk decisions. 2007; 1–9.
474. Nilsson JP, Söderström M, Karlsson AU, et al. Less effective executive functioning after one night's sleep deprivation. *J Sleep Res* 2005; 14: 1–6.
475. Sagaspe P, Sanchez-Ortuno M, Charles A, et al. Effects of sleep deprivation on Color-Word, Emotional, and Specific Stroop interference and on self-reported anxiety. *Brain Cogn* 2006; 60: 76–87.
476. Sleep Deprivation Elevates Expectation of Gains and Attenuates Response to Losses Following Risky Decisions. 2007; 1–7.
477. Tucker AM, Whitney P, Belenky G, et al. Effects of Sleep Deprivation on Dissociated Components of Executive Functioning. *Sleep* 2010; 33: 47–57.
478. Jones K, Harrison Y. Frontal lobe function, sleep loss and fragmented sleep. *Sleep Med Rev* 2001; 5: 463.
479. Plessow F, Kiesel A, Petzold A, et al. Chronic sleep curtailment impairs the flexible implementation of task goals in new parents. *J Sleep Res*. Epub ahead of print 2010. DOI: JSR878 [pii]10.1111/j.1365-2869.2010.00878.x.
480. Phillips LH. Do 'frontal tests' measure executive function? Issues of assessment and evidence from fluency tests. *Methodol Front Exec Funct* 1997; 191–213.
481. Whitney P, Jameson T, Hinson JM. Impulsiveness and executive control of working memory. *Pers Individ Dif* 2004; 37: 417–428.
482. Epstein LH, Leddy JJ, Temple JL, et al. Food reinforcement and eating: a multilevel analysis. *Psychol Bull* 2007; 133: 884–906.
483. Epstein LH, Salvy SJ, Carr KA, et al. Food reinforcement, delay discounting and obesity. *Physiol Behav* 2010; 100: 438–445.
484. Mazur JE. Predicting the strength of a conditioned reinforcer: Effects of delay and uncertainty. *Curr Dir Psychol Sci* 1993; 2: 70–74.
485. Daugherty JR, Brase GL. Taking time to be healthy: Predicting health

- behaviors with delay discounting and time perspective. *Pers Individ Dif* 2010; 48: 202–207.
486. Bradford WD. The Association Between Individual Time Preferences and Health Maintenance Habits. *Med Decis Mak* 2009; 30: 99–112.
 487. Ikeda S, Kang M-I, Ohtake F. Hyperbolic discounting, the sign effect, and the body mass index. *J Health Econ* 2010; 29: 268–284.
 488. Weller RE, Cook 3rd EW, Avsar KB, et al. Obese women show greater delay discounting than healthy-weight women. *Appetite* 2008; 51: 563–569.
 489. Wansink B, Sobal J. Mindless eating: The 200 daily food decisions we overlook. *Environ Behav* 2007; 39: 106–123.
 490. Wansink B, Payne CR. Counting bones: environmental cues that decrease food intake. *Percept Mot Ski* 2007; 104: 273–276.
 491. The influence of food portion size and energy density on energy intake: implications for weight management. 2005; 1–6.
 492. Ledikwe JH, Ello-Martin JA, Rolls BJ. Portion sizes and the obesity epidemic. *J Nutr* 2005; 135: 905.
 493. Lavin JG, Lawless HT. Effects of color and odor on judgments of sweetness among children and adults. *Food Qual Pref* 1998; 9: 283–89.
 494. Brobeck JR. Food intake as a mechanism of temperature regulation. *Yale J Biol Med* 1948; 20: 545–552.
 495. Westerterp-Plantenga MS, Westerterp-Plantenga MS. Effects of extreme environments on food intake in human subjects. *Proc Nutr Soc* 1999; 58: 791–798.
 496. Murray R. The effects of consuming carbohydrate-electrolyte beverages on gastric emptying and fluid absorption during and following exercise. *Sport Med* 1987; 4: 322–351.
 497. Clendenen VI, Herman CP, Polivy J. Social facilitation of eating among friends and strangers. *Appetite* 1994; 23: 1–13.
 498. Pliner P, Bell R, Kinchla M, et al. Time to eat? The impact of time facilitation and social facilitation on food intake. 2003, pp. 20–24.
 499. Wansink B, Painter JE, Lee YK. The office candy dish: proximity's influence on estimated and actual consumption. *Int J Obes* 2006; 30: 871–875.
 500. Wansink B. ENVIRONMENTAL FACTORS THAT INCREASE THE FOOD INTAKE AND CONSUMPTION VOLUME OF UNKNOWING CONSUMERS*. *Annu Rev Nutr* 2004; 24: 455–479.
 501. Wansink - Bad Popcorn in big buckets portion size can influence intake as much as taste. 2005; 1–5.
 502. Wansink B, Painter JE, North J. Bottomless bowls: why visual cues of portion size may influence intake. *Obes Res* 2005; 13: 93–100.
 503. Stroebele N, De Castro JM. Effect of ambience on food intake and food choice. *Nutrition* 2004; 20: 821–838.
 504. Rolls BJ, Roe LS, Kral T V, et al. Increasing the portion size of a packaged snack increases energy intake in men and women. *Appetite* 2004; 42: 63–69.

505. Wansink B, Wansink CS. The largest Last Supper: depictions of food portions and plate size increased over the millennium. *Int J Obes* 2010; 1–2.
506. Nielsen SJ, Popkin BM. Patterns and trends in food portion sizes, 1977–1998. *JAMA* 2003; 289: 450.
507. Smiciklas-Wright H, Mitchell DC, Mickle SJ, et al. Foods commonly eaten in the United States, 1989–1991 and 1994–1996: Are portion sizes changing? *J Am Diet Assoc* 2003; 103: 41–47.
508. Matthiessen J, Fagt S, Biloft-Jensen A, et al. Size makes a difference. *Public Health Nutr* 2007; 6: 65–72.
509. Young LR, Nestle M. The contribution of expanding portion sizes to the US obesity epidemic. *Am J Public Health* 2002; 92: 246.
510. Westenhoefer J, Broeckmann P, Munch AK, et al. Cognitive control of eating behaviour and the disinhibition effect. *Appetite* 1994; 23: 27–41.
511. Westenhoefer J, Pudel V, Maus N. Some restrictions on dietary restraint. *Appetite* 1990; 14: 133–137.
512. Lawson OJ, Williamson DA, Champagne CM, et al. The association of body weight, dietary intake, and energy expenditure with dietary restraint and disinhibition. *Obes Res* 1995; 3: 153–161.
513. Dykes J, Brunner EJ, Martikainen PT, et al. Socioeconomic gradient in body size and obesity among women: the role of dietary restraint, disinhibition and hunger in the Whitehall II study. *Int J Obes Relat Metab Disord* 2004; 28: 262–268.
514. Waadegaard M, Davidsen M, Kjoller M. Obesity and prevalence of risk behaviour for eating disorders among young Danish women. *Scand J Public Health* 2009; 37: 736–743.
515. Polivy J, Herman CP. Diagnosis and treatment of normal eating. *J Consult Clin Psychol* 1987; 55: 635–644.
516. Jauch-Chara K, Hallschmid M, Schmid SM, et al. Sleep loss does not aggravate the deteriorating effect of hypoglycemia on neurocognitive function in healthy men. *Psychoneuroendocrinology* 2010; 35: 624–628.
517. Higgs S. Memory for recent eating and its influence on subsequent food intake. *Appetite* 2002; 39: 159–166.
518. Meerlo P, Mistlberger RE, Jacobs BL, et al. New neurons in the adult brain: the role of sleep and consequences of sleep loss. *Sleep Med Rev* 2009; 13: 187–194.
519. Turner SA, Luszczynska A, Warner L, et al. Emotional and uncontrolled eating styles and chocolate chip cookie consumption. A controlled trial of the effects of positive mood enhancement. *Appetite* 2010; 54: 143–149.
520. Evers C, Marijn Stok F, de Ridder DTD. Feeding Your Feelings: Emotion Regulation Strategies and Emotional Eating. *Personal Soc Psychol Bull* 2010; 36: 792–804.
521. St-Onge M-P, McReynolds A, Trivedi ZB, et al. Sleep restriction leads to increased activation of brain regions sensitive to food stimuli. *Am J Clin Nutr* 2012; 95: 818–24.

522. Benedict C, Brooks SJ, O'Daly OG, et al. Acute sleep deprivation enhances the brain's response to hedonic food stimuli: an fMRI study. *J Clin Endocrinol Metab* 2012; 97: E443-7.
523. St-Onge MP, Wolfe S, Sy M, et al. Sleep restriction increases the neuronal response to unhealthy food in normal-weight individuals. *Int J Obes*. Epub ahead of print 2013. DOI: 10.1038/ijo.2013.114.
524. Greer S, Goldstein A, Walker M. The impact of sleep deprivation on food desire in the human brain. *Nat Commun* 2013; 4: 2259.
525. Rechtschaffen A, Wolpert EA, Dement WC, et al. Nocturnal Sleep of Narcoleptics. *Electroencephalogr Clin Neurophysiol* 1963; 15: 599–609.
526. Montplaisir J, Billiard M, Takahashi S, et al. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. *Biol Psychiatry* 1978; 13: 73–89.
527. Baker TL, Guilleminault C, Nino-Murcia G, et al. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. *Sleep* 1986; 9: 232–242.
528. Rogers AE, Aldrich MS, Caruso CC. Patterns of sleep and wakefulness in treated narcoleptic subjects. *Sleep* 1994; 17: 590–597.
529. A Randomized Trial Evaluating the Effectiveness of Sodium Oxybate Therapy on Quality of Life in Narcolepsy. 2006; 1–6.
530. Hypocretin Deficiency in Narcoleptic Humans Is Associated with Abdominal Obesity. 2003; 1–8.
531. Eating Disorder and Metabolism in Narcoleptic Patients. 2007; 1–7.
532. Fortuyn HA, Swinkels S, Buitelaar J, et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. *Sleep* 2008; 31: 335–341.
533. Ford ES, Cunningham TJ, Croft JB. Trends in Self-Reported Sleep Duration among US Adults from 1985 to 2012. *Sleep* 2015; 38: 829–832.
534. Institute of Medicine (US) Committee on Sleep Medicine and Research X. *Sleep Disorders and Sleep Deprivation*. Washington, D.C.: National Academies Press. Epub ahead of print September 2006. DOI: 10.17226/11617.
535. Lobstein T, Baur L, Uauy R, et al. Obesity in children and young people: a crisis in public health. *Obes Rev* 2004; 5 Suppl 1: 4–104.
536. Bin YS, Marshall NS, Glozier N. Secular trends in adult sleep duration: a systematic review. *Sleep Med Rev* 2012; 16: 223–230.
537. Bin YS, Marshall NS, Glozier N. Sleeping at the limits: the changing prevalence of short and long sleep durations in 10 countries. *Am J Epidemiol* 2013; 177: 826–833.
538. Knutson KL, Van Cauter E, Rathouz PJ, et al. Trends in the prevalence of short sleepers in the USA: 1975-2006. *Sleep* 2010; 33: 37–45.
539. Ohayon MM, Carskadon MA, Guilleminault C, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan.

- Sleep* 2004; 27: 1255–1273.
540. Youngstedt SD, Goff EE, Reynolds AM, et al. Objective measures of sleep quality have not declined over the last 50 years. *Sleep Med Rev* 2016; 30: 108–109.
 541. Cain SW, Filtner AJ, Phillips CL, et al. Enhanced preference for high-fat foods following a simulated night shift. *Scand J Work Env Heal*. Epub ahead of print 2015. DOI: 10.5271/sjweh.3486.
 542. Fang Z, Spaeth AM, Ma N, et al. Altered salience network connectivity predicts macronutrient intake after sleep deprivation. *Sci Rep* 2015; 5: 8215.
 543. Libedinsky C, Massar SA, Ling A, et al. Sleep deprivation alters effort discounting but not delay discounting of monetary rewards. *Sleep* 2013; 36: 899–904.
 544. Venkatraman V, Huettel SA, Chuah LY, et al. Sleep deprivation biases the neural mechanisms underlying economic preferences. *J Neurosci* 2011; 31: 3712–3718.
 545. Cappuccio FP, D’Elia L, Strazzullo P, et al. Quantity and Quality of Sleep and Incidence of Type 2 Diabetes: A systematic review and meta-analysis. *Diabetes Care* 2010; 33: 414–420.
 546. Magee L, Hale L. Longitudinal associations between sleep duration and subsequent weight gain: a systematic review. *Sleep Med Rev* 2012; 16: 231–241.
 547. Tsatsoulis A, Mantzaris MD, Bellou S, et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment - an evolutionary perspective. *Metabolism* 2013; 62: 622–633.
 548. Sellayah D, Cagampang FR, Cox RD. On the evolutionary origins of obesity: a new hypothesis. *Endocrinology* 2014; 155: 1573–1588.
 549. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. *Nat Rev Immunol* 2008; 8: 923–934.
 550. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. *Annu Rev Immunol* 2011; 29: 415–445.
 551. Calay ES, Hotamisligil GS. Turning off the inflammatory, but not the metabolic, flames. *Nat Med* 2013; 19: 265–267.
 552. Chan JC, Cho NH, Tajima N, et al. Diabetes in the Western Pacific Region--past, present and future. *Diabetes Res Clin Pr* 2014; 103: 244–255.
 553. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005; 115: 1111–1119.
 554. Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. *Immunol Rev* 2012; 249: 218–238.
 555. Clark I, Atwood C, Bowen R, et al. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer’s disease links numerous treatment rationales. *Pharmacol Rev* 2012; 64: 1004–1026.
 556. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine

- concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* 2002; 106: 2067–2072.
557. Black PH. The inflammatory consequences of psychological stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. *Med Hypotheses* 2006; 67: 879–891.
558. Rodriguez-Hernandez H, Simental-Mendia LE, Rodriguez-Ramirez G, et al. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. *Int J Endocrinol* 2013; 2013: 678159.
559. Ebrahimi A, Nabipour I, Vahdat K, et al. High sensitivity C-reactive protein is associated with the metabolic syndrome independent to viral and bacterial pathogen burden. *Diabetes Res Clin Pr* 2009; 84: 296–302.
560. Dandona P, Chaudhuri A, Ghanim H, et al. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. *Am J Cardiol* 2007; 99: 15B–26B.
561. Dandona P, Chaudhuri A, Ghanim H, et al. Insulin as an anti-inflammatory and antiatherogenic modulator. *J Am Coll Cardiol* 2009; 53: S14-20.
562. O’Keefe JH, Vogel R, Lavie CJ, et al. Organic fitness: physical activity consistent with our hunter-gatherer heritage. *Phys Sport* 2010; 38: 11–18.
563. O’Keefe JH, Vogel R, Lavie CJ, et al. Exercise like a hunter-gatherer: a prescription for organic physical fitness. *Prog Cardiovasc Dis* 2011; 53: 471–479.
564. Fernandez-Real JM, Garcia-Fuentes E, Moreno-Navarrete JM, et al. Fat overload induces changes in circulating lactoferrin that are associated with postprandial lipemia and oxidative stress in severely obese subjects. *Obes (Silver Spring)* 2010; 18: 482–488.
565. Holmer-Jensen J, Karhu T, Mortensen LS, et al. Differential effects of dietary protein sources on postprandial low-grade inflammation after a single high fat meal in obese non-diabetic subjects. *Nutr J* 2011; 10: 115.
566. Luchsinger JA. Diabetes, related conditions, and dementia. *J Neurol Sci* 2010; 299: 35–38.
567. Spreadbury I. Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity. *Diabetes Metab Syndr Obes* 2012; 5: 175–189.
568. Speakman JR, Mitchell SE. Caloric restriction. *Mol Asp Med* 2011; 32: 159–221.
569. Mattson MP. Energy intake, meal frequency, and health: a neurobiological perspective. *Annu Rev Nutr* 2005; 25: 237–260.
570. Mattson MP, Wan R. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. *J Nutr Biochem* 2005; 16: 129–137.
571. Redman LM, Ravussin E. Caloric restriction in humans: impact on physiological, psychological, and behavioral outcomes. *Antioxid Redox Signal* 2011; 14: 275–287.
572. Li Q. Effect of forest bathing trips on human immune function. *Environ*

- Health Prev Med* 2010; 15: 9–17.
573. Li Q, Otsuka T, Kobayashi M, et al. Acute effects of walking in forest environments on cardiovascular and metabolic parameters. *Eur J Appl Physiol* 2011; 111: 2845–2853.
 574. Park BJ, Tsunetsugu Y, Kasetani T, et al. The physiological effects of Shinrin-yoku (taking in the forest atmosphere or forest bathing): evidence from field experiments in 24 forests across Japan. *Env Heal Prev Med* 2010; 15: 18–26.
 575. Laposky AD, Bass J, Kohsaka A, et al. Sleep and circadian rhythms: key components in the regulation of energy metabolism. *FEBS Lett* 2008; 582: 142–151.
 576. Copinschi G. Metabolic and endocrine effects of sleep deprivation. *Essent Psychopharmacol* 2005; 6: 341–347.
 577. Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. *Obes (Silver Spring)* 2008; 16: 643–653.
 578. Van Cauter E, Spiegel K, Tasali E, et al. Metabolic consequences of sleep and sleep loss. *Sleep Med* 2008; 9 Suppl 1: S23-8.
 579. Krause AJ, Simon EB, Mander BA, et al. The sleep-deprived human brain. *Nat Rev Neurosci* 2017; 18: 404–418.
 580. Chen X, Beydoun MA, Wang Y. Is sleep duration associated with childhood obesity? A systematic review and meta-analysis. *Obes (Silver Spring)* 2008; 16: 265–274.
 581. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. *Ann N Y Acad Sci* 2008; 1129: 287–304.
 582. Marshall NS, Glozier N, Grunstein RR. Is sleep duration related to obesity? A critical review of the epidemiological evidence. *Sleep Med Rev* 2008; 12: 289–298.
 583. Fatima Y, Doi SA, Mamun AA. Sleep quality and obesity in young subjects: a meta-analysis. *Obes Rev* 2016; 17: 1154–1166.
 584. Kim K, Shin D, Jung GU, et al. Association between sleep duration, fat mass, lean mass and obesity in Korean adults: the fourth and fifth Korea National Health and Nutrition Examination Surveys. *J Sleep Res* 2017; 26: 453–460.
 585. Carter PJ, Taylor BJ, Williams SM, et al. Longitudinal analysis of sleep in relation to BMI and body fat in children: the FLAME study. *BMJ* 2011; 342: d2712.
 586. Chaput JP, Despres JP, Bouchard C, et al. The Association between Short Sleep Duration and Weight Gain Is Dependent on Disinhibited Eating Behavior in Adults. *Sleep* 2011; 34: 1291–1297.
 587. Eisenmann JC, Ekkekakis P, Holmes M. Sleep duration and overweight among Australian children and adolescents. *Acta Paediatr* 2006; 95: 956–963.
 588. Nam GE, Han K, Kim DH, et al. Sleep duration is associated with body fat and muscle mass and waist-to-height ratio beyond conventional obesity parameters in Korean adolescent boys. *J Sleep Res* 2017; 26: 444–452.

589. Park YJ, Lee WC, Yim HW, et al. [The association between sleep and obesity in Korean adults]. *J Prev Med Public Heal* 2007; 40: 454–460.
590. Patel SR, Malhotra A, White DP, et al. Association between reduced sleep and weight gain in women. *Am J Epidemiol* 2006; 164: 947–954.
591. Rutters F, Gerver WJ, Nieuwenhuizen AG, et al. Sleep duration and body-weight development during puberty in a Dutch children cohort. *Int J Obes* 2010; 34: 1508–1514.
592. Snell EK, Adam EK, Duncan GJ. Sleep and the body mass index and overweight status of children and adolescents. *Child Dev* 2007; 78: 309–323.
593. Wang J, Adab P, Liu W, et al. Prevalence of adiposity and its association with sleep duration, quality, and timing among 9-12-year-old children in Guangzhou, China. *J Epidemiol*. Epub ahead of print 2017. DOI: 10.1016/j.je.2016.11.003.
594. Capers PL, Fobian AD, Kaiser KA, et al. A systematic review and meta-analysis of randomized controlled trials of the impact of sleep duration on adiposity and components of energy balance. *Obes Rev* 2015; 16: 771–782.
595. Akiyama M, Yuasa T, Hayasaka N, et al. Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated mice. *Eur J Neurosci* 2004; 20: 3054–3062.
596. Nedeltcheva A V, Kilkus JM, Imperial J, et al. Sleep curtailment is accompanied by increased intake of calories from snacks. *Am J Clin Nutr* 2009; 89: 126–133.
597. Laposky AD, Bradley MA, Williams DL, et al. Sleep-wake regulation is altered in leptin-resistant (db/db) genetically obese and diabetic mice. *Am J Physiol Regul Integr Comp Physiol* 2008; 295: R2059-66.
598. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. *Lancet* 1999; 354: 1435–1439.
599. Sutcliffe JG, de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. *J Neurosci Res* 2000; 62: 161–168.
600. Leproult R, Van Reeth O, Byrne MM, et al. Sleepiness, performance, and neuroendocrine function during sleep deprivation: effects of exposure to bright light or exercise. *J Biol Rhythm* 1997; 12: 245–258.
601. Dinges DF, Douglas SD, Hamarman S, et al. Sleep deprivation and human immune function. *Adv Neuroimmunol* 1995; 5: 97–110.
602. Rogers NL, Szuba MP, Staab JP, et al. Neuroimmunologic aspects of sleep and sleep loss. *Semin Clin Neuropsychiatry* 2001; 6: 295–307.
603. Zager A, Andersen ML, Ruiz FS, et al. Effects of acute and chronic sleep loss on immune modulation of rats. *Am J Physiol Regul Integr Comp Physiol* 2007; 293: R504-9.
604. Vgontzas AN, Bixler EO, Lin HM, et al. IL-6 and its circadian secretion in humans. *Neuroimmunomodulation* 2005; 12: 131–140.
605. Easton A, Meerlo P, Bergmann B, et al. The suprachiasmatic nucleus regulates sleep timing and amount in mice. *Sleep* 2004; 27: 1307–1318.

606. Challet E, Turek FW, Laute M, et al. Sleep deprivation decreases phase-shift responses of circadian rhythms to light in the mouse: role of serotonergic and metabolic signals. *Brain Res* 2001; 909: 81–91.
607. Laposky A, Easton A, Dugovic C, et al. Deletion of the mammalian circadian clock gene BMAL1/Mop3 alters baseline sleep architecture and the response to sleep deprivation. *Sleep* 2005; 28: 395–409.
608. Sehgal A, Mignot E. Genetics of sleep and sleep disorders. *Cell* 2011; 146: 194–207.